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Emerging as an effective option, immunotherapy is gradually being recognized by 
the cancer treatment community. However, due to its wide use of viral vectors for gene 
delivery, many limitations and safety concerns impede its adoption in clinical practice. 
This promotes the emergence of many non-viral gene delivery methods including the use 
of inorganic or organic nanoparticles to carry and deliver genetic probes as complexes 
through chemical mechanisms and the use of mechanical or electrical forces to physically 
breakdown delivery barriers of the cell membrane to allow quick probe internalization. 
Compared to the former (chemical methods), the latter (physical methods) shows 
advantages in fast and efficient delivery performance, among which electroporation has 
attracted the most attention in the past two decades. Electroporation designates the use of 
short, high-voltage pulses to make the subjected cell membrane permeable. It has many 
advantages like simple operation, quick delivery, non-restrictions on gene or cell types, 
and low cost. However, compared to the viral delivery method, electroporation still faces 
great challenges in terms of transfection efficiency. To solve these problems, we 
developed a carbon nanotube (CNT) based micropillar array electrode (MAE) structure 
and nanosecond electroporation pulse schemes to improve the overall transfection 
performance of electroporation technology. The new carbon nanotube micropillar array 
electrodes are used to replace the traditional aluminum plate electrodes. The superior 
conductivity of CNTs on the micropillar surface makes the new electrode as good as their 
iv 
traditional counterparts in terms of conductance while its inert surface avoids undesired 
electrochemical reactions and the release of Al3+ ions in the cell buffered solution which 
are believed to be toxic to cells. More important, the epoxy base of the micropillars helps 
partially embed those CNTs and fix them permanently on the electrode surface while the 
exposed portion of CNTs serves as separated nanoelectrodes on the micropillar surface to 
focus the electric pulse strength. This allows cells of different sizes to receive uniform 
treatment during electroporation, resulting in significant improvement in the transfection 
efficiency of genetic probes. Besides the CNT nanoelectrodes, we also applied 
nanosecond pulses to further improve the transgene expression of electroporation by 
deeper penetration than the traditional/standard millisecond electrical pulses. Under those 
nanosecond electrical pulses, not only does the cell membrane becomes more fragile but 
also the cell nuclear membrane becomes permeable. This allows genetic probes to enter 
the cell nucleus more quickly to start the transcription process eventually speeding up the 
overall transfection kinetics. 
In this project, leukemia cells and carcinoma cells were used as the representative 
suspension and adherent cell models respectively to demonstrate these two new 
electroporation technologies. Plasmids encoding pMaxGFP and small interfering RNA 
that precisely silence GFP translation were used as large and small genetic probe 
representatives to test their delivery effectiveness. We found that carbon nanotube 
micropillar array electrodes can achieve three times or more transfection efficiency than 
the commercial electroporation counterparts without sacrificing cell viability. Combining 
nanosecond and millisecond pulse scheme, the needed transgene expression time was 
shortened by nearly 20 hours, demonstrating with GFP plasmids. These new 
v 
electroporation technologies were further applied to treat model blood cells by mixing 
primary blood cells with K562 cells at various ratios. The results show that our nano 
electroporation system could double the transfection efficiency compared to the 
commercial electroporation system for both plasmid and therapeutic microRNA, miR-
29b. The targeted protein level of miR-29b is further downregulated 20-25% from what is 
achieved in commercial electroporation systems. Its success might further promote the 
wide adoption of electroporation technology in cell immunotherapy. 
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1.1 Research Hypothesis 
1.1.1 Central Problems 
Cancer is currently one of the most lethal and morbid diseases for human beings. 
In recent years, immunotherapy has been used as a new and proven method in cancer 
treatment. Immunotherapy strengthens the patient’s immune response to fight against 
cancer and tumors by inducing stimulation and other methods (Kruger et al., 2019). 
However, the viral transfection method widely used in immunotherapy carries significant 
safety risks and long treatment duration. In addition, viral cancer immunotherapy requires 
some in vitro transfection processes and multiple lymphatic injections during the 
treatment period, causing great pain to patients. 
Efficient non-viral transfection methods are more benign and are considered as 
viral delivery alternatives as no safety concerns. Among different non-viral transfection 
methods, electroporation is attractive in immunotherapy due to its many advantages such 
as quick delivery and almost no restrictions on the cell type or delivery probes. However, 
currently available electroporation technology still has several disadvantages, including 
low transfection efficiency, high pulse voltage caused undesired effects, and 
undiscriminating electroporation on cells regardless of their different sizes. 
2 
1.1.2 Objectives 
We propose some new electroporation technologies to improve their effectiveness 
in immunotherapy. First, a Carbon Nanotube Micropillars Electroporation (CNTPs) 
system is developed to improve the transfection efficiency for DNA and RNA probes 
delivery. In this CNTPs system, cells are sandwiched between two plate electrodes with 
one electrode made of carbon nanotube covered micropillars on the surface. When cells 
are loaded onto its surface, the number of micropillars each cell faces varies with its size. 
That means, for a large cell, it will receive more electroporation sites. As a consequence, 
more hydrophilic pores will be produced on its cell membrane after electroporation than a 
small cell. The carbon nanotubes on top of each micropillar make the pulse signal highly 
concentrated in spots on the cell membrane at the nanometer resolution level.  
Besides the advance of CNTPs on electroporation, we also look into the use of 
pulse signals with nanosecond duration to further improve the electroporation 
transfection efficiency and kinetics. Short nanosecond pulses were found useful to 
increase the permeability of cell membranes and other membrane structures of 
intracellular organelles, either temporarily or permanently (Beebe et al., 2003; Chopinet 
et al., 2013; Ruzgys et al., 2018). Considering its potential to disrupting the nuclear 
membrane (Tekle et al., 2005; Schoenbach et al., 2001), we hypothesize that appropriate 
combination of nanosecond pulse treatment with traditional electroporation using 
millisecond pulses might help promote quick nuclear entry of plasmids after their release 




Based on these hypotheses, carbon nanotube micropillars electrodes were 
fabricated and applied in size-specific electroporation treatment. Briefly, SU-8 
photoresist was first coated on a Si (100) wafer to create a micropillar array master mold. 
A PDMS mold with a negative replica of the SU-8 micropillar structure was then coated 
with a thin layer of carbon nanotube powder. The PDMS mold and another Si wafer piece 
coated with another SU-8 photoresist layer were then pressed together and exposed under 
UV light to solidify the SU-8 photoresist layer. After removing the PDMS mold, 
micropillars of 2 µm in diameter and a pitch size of 2 µm (Figure 1-1a) were defined in a 
12 mm ×12 mm region. On the surface of these SU-8 micropillars, carbon nanotubes are 
partially embedded inside photoresist (Figure 1-1b). This not only ensures excellent 
electrical conductivity for the whole micropillar electrode but also provides many 
nanoelectrodes on the surface of those micropillars to further focus the electric pulse 
strength and makes uniform pulse treatment on cell membrane regardless the different 






(a)                                                                 (b) 
Figure 1-1: (a) the SEM image of 2µm micropillar. (b) the SEM image of 2µm Carbon 
Nanotube Micropillars. 
Furthermore, a home-made circuit board was used to generate nanosecond pulses 
and integrated into a flow-through nano-electroporation system. It includes three separate 
units (a pulse generation unit, a power supply unit and a capacitor) which are connected 
with an n-channel enhanced radio frequency metal-oxide-semiconductor field-effect 
transistor (MOSFET). The nanosecond pulses with high pulse voltage were delivered in a 
microfluidic channel which was milled on a piece of polymethyl methacrylate board. 
Cells flow through the channel and pass the nanosecond pulsatile electric field to 
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(a)                                                               (b) 
Figure 1-2: (a) schematic of electric circuit design (b) schematic of the microfluidic 
channel with Pt electrodes integrated on channel wall from both sides 
We evaluated our hypotheses and concepts with these two new electroporation 
technologies by looking into DNA and RNA probe delivery to both adherent cells (e.g., 
CT-26) and suspended cells (e.g., K562), as well as a model primary whole blood cells. 
The delivery enhancement was evaluated by measuring the cell viability and transfection 
efficiency of those targeting DNA and RNA probes. 
1.3 Structure 
Chapter 1 outlines the central problems and objectives of this research project. It 
also introduces briefly our research approaches and organization of this dissertation. 
Chapter 2 provides a literature review of relevant research work. This review includes 
cancer immunotherapy options, gene transfection methods, electroporation mechanism 
study, and current state-of-art micro/nano electroporation systems. Chapter 3 
demonstrates the carbon nanotube micropillars electrode enhanced electroporation in 
mammalian cell transfection. Chapter 4 demonstrates the nanosecond electroporation 
6 
scheme combining with millisecond pulses and its enhancement on mammalian cell 
transfection. Chapter 5 demonstrates the coupling of these two new electroporation 
technologies and the enhanced gene probe delivery in model whole blood samples. 
Chapter 6 summarizes the results of the entire dissertation and recommends some work 







2.1 Cancer Therapy 
Cancer is one of the world’s biggest public health problems. In 2018, there were 
about 1,735,350 new cancer cases in the United States, and 609,640 cancer deaths were 
projected (Siegel et al., 2018). As shown in Figure 2-1, cancer is one of the most fatal 
diseases in the United States. For many years, people have been searching for cancer 
treatments through surgery, chemotherapy, and radiation therapy (Figure 2-2). However, 
these traditional treatments have some limitations, like poor effectiveness, and/or strong 
side effects, which often seriously affect the life quality of patients. Some new 
therapeutic drugs such as imatinib (Gleevec®) and trastuzumab (Herceptin®) have 
emerged in the past two decades (Fischer et al., 2003). These drugs can target cancer 
cells by homing in on specific molecular changes seen primarily in those cells. For 
example, imatinib is a BCR-ABL kinase inhibitor that can inhibit the activity of tyrosine 
kinase and promote the apoptosis of cancer cells (An et al., 2010). This kind of targeted 
therapy has already become the standard treatment for many cancer treatments (Jabbour 
& Hagop, 2018). However, because its significant side effects on harming to the patient’s 
immune system, such as damaging the functions of human regulatory T cells and antigen-
presenting cells (Mughal, 2010), scientists are continuously looking for new cancer 
treatment methods that can inhibit the growth of cancer cells and tumors while still 
8 
protect patient’s immune system. 
 
Figure 2-1: Age-adjusted death rates for the ten leading causes of death in the United 
States, 2016, and 2017. 
2.2 Immunotherapy 
With the development of molecular biology and immunology, immunotherapy has 
emerged as a new attractive method in recent years and gradually become recognized by 
the cancer treatment community (Khalil et al., 2016). There are two main types of 
immunotherapy: active immunotherapy and passive immunotherapy. Active 
immunotherapy can activate or stimulate the patient’s immune system, enabling its better 
reorganization on tumor antigens or specific aggregation and consequence on tumor cell 
attack (Davis, 2000; Oiseth & Aziz, 2017). Passive immunotherapy uses external 
substances, such as monoclonal antibodies, lymphocytes, and cytokines, to exert 
antitumor effects. In 2008, The New England Journal of Medicine reported a successful 
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immunotherapy case for advanced melanoma treatment (Hunder et al., 2008). The patient 
was a case of multiple metastases throughout the body. All the lesions of the patient 
disappeared after being treated with autologous CD4+ T cells. The 2011 Nobel Prize in 
Physiology or Medicine was also awarded to three scientists who were engaged in tumor 
immunotherapy research (The Nobel Prize in Physiology or Medicine 2011). In 2018, 
James P. Allison and Tasuku Honjo received the Nobel Prize in Physiology or Medicine 
for their discovery of cancer therapy by inhibition of negative immune regulation (The 
Nobel Prize in Physiology or Medicine 2018). These all bode well for the broad prospect 
of immunotherapy in the field of malignant tumor treatment. 
 
Figure 2-2: Cancer treatment options. Including Surgery, Hormone Therapy, Bone 
Marrow Transplantation, Chemotherapy, Targeted Therapy, Radiation Therapy, and 
Immunotherapy. 
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2.2.1 Dendritic Cell-Based Immunotherapy 
In immunotherapy, dendritic cell-based (DC) immunotherapy was the first one 
that got approved by the U.S. Food and Drug Administration (FDA) in April 2010 
(Cheever & Higano, 2011). DC immunotherapy uses the principle of antigen 
presentation. DC cells can collect tumor antigens and present them to T cells to activate 
them, and can promote targeted enrichment of T cells, which is a crucial antigen-
presenting cell. DC cells are sparsely distributed in blood and tissues. In DC cell-based 
immunotherapy, immature DCs were collected from whole blood or white blood cell 
separation first. Then, artificial antigens were induced and expressed in DCs by mRNA 
encoding tumor-associated antigens (TAAs) (Nair et al.,2002; Müller et al., 2004; 
Nencioni et al., 2003; Milazzo et al., 2003) as peptides or proteins that carry tumor 
antigens (Oneill & Nina, 2005). The mature DCs were then injected back into the 
patient’s body via lymphatic injection, thereby stimulating T cells to complete the 
immune response (Fujiwara et al., 2012; Roberts et al., 2016) (Figure 2-3). DC 
immunotherapy was used to treat tumors caused by DC function lost or defected. Because 
DC immunotherapy can help restore the specificity of activated T cells by repairing, 
restoring, and enhancing the patient’s cellular immune function, it breaks the body’s 
immune systemic and local tolerance state, thereby achieving systemic and local 
reconstruction of the body’s immunity (Lesterhuis et al., 2011). 
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Figure 2-3: Schematic of Dendritic cell-based (DC) immunotherapy principle. 
2.2.2 Chimeric Antigen Receptor T-Cell Immunotherapy 
Chimeric Antigen Receptor T-Cell Immunotherapy (CAR T-cell therapy) is 
another representative immunotherapy method. In July 2017, the FDA approved 
Novartis’s CAR T-cell product CTL019 in the treatment of relapsed or refractory 
children and young B acute lymphoblastic leukemia (ALL) (Philippidis, 2017). In 
addition to leukemia, CAR-T therapy is also widely used in some refractory lymphomas, 
such as the treatment of B-cell non-Hodgkin lymphoma (NHL) (Chavez et al., 2019). 
This therapy involves extracting T-cells from the patients’ Lymph node or Spinal cord, 
followed by genetically modification in vitro using viral vectors to express artificial 
Chimeric antigen receptor (CAR). CAR mainly includes three parts, namely the 
extracellular single-chain variable fragment scFv, a transmembrane region, and a single 
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intracellular activation signal CD3ζ or FcεRIγ (Srivastava & Stanley, 2015). Among 
them, scFv is a single-chain antibody that can recognize tumor surface antigens outside 
the cell membrane while CD3ζ or FcεRIγ is used for signal transmission. CAR can 
stimulate T cells to carry out further immune responses after recognizing cancer cell 
antigens, and the two are connected by transmembrane regions (Miliotou & Lefkothea, 
2018) (Figure 2-4). After being modified and expressed in vitro, T-cells are further 
expanded and eventually returned to the patient. Modified T cells can kill tumor cells 
with more accurate identification and a much stronger effect than traditional 
chemotherapy or radiotherapy. They will not disappear quickly even after the tumor cells 
were eliminated and can circulate in the patient's body for a long time to monitor and 
prevent the recurrence of cancer (Yáñez et al., 2019).  
 
Figure 2-4: Schematic of CAR T-cell immunotherapy principle. (Miliotou and 
Lefkothea, 2018) 
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2.2.3 Natural Killer Cell Immunotherapy 
Natural Killer cells (NK cell), with large particles in the cytoplasm, were 
developed from bone marrow lymphoid stem cells, whose differentiation and 
development depend on the bone marrow or thymus microenvironment. NK cells were 
mainly distributed in peripheral blood and spleen. They can either directly contact and 
kill target cells by rupturing their cell membrane or secrete perforin and tumor necrosis 
factor to destroy target cells. Although NK cells are the leading members of innate anti-
tumor immunity, tumors have also formed various strategies to escape NK cells from 
trapping or impair NK cells’ function. These strategies greatly affect the actual 
effectiveness of NK cell therapy (Sun et al., 2015; Veuillen et al., 2012; Reiners et al., 
2013; Paul et al., 2016). In 2018, A new antibody, named MAB-7C6  that targeted 
MICA and MICB, was proposed to suppress the tumor's escape strategies (Andrade et al., 
2018). By isolating NK cells from human peripheral blood and using viral vectors to 
induce the medication of NK cells and the secreting of this antibody, this new NK 
therapy has achieved significant positive results in the treatment of lung cancer and 
melanoma (Andrade et al., 2018). Similar to CAR-T therapy, Chimeric Antigen Receptor 
Natural Killer (CAR-NK) cell immunotherapy is currently being extensively developed 
(Ingegnere et al., 2019). In this combined immunotherapy strategy, CAR-NK cells are 
genetically modified NK cells that can express specific antigens without being restricted 
by autologous cells. Because it does not cause Graft-versus-host disease, this therapy is 
very safe compared to other treatment options (Rubnitz et al., 2010; Miller et al., 2005; 
Shaffer et al., 2016) (Figure 2-5). 
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Figure 2-5: Natural Killer cells immunotherapy principle diagram. (Guillerey et al., 
2016) 
2.3 The Shortcomings and Side Effects of Immunotherapy 
Although immunotherapy achieves great success in cancer treatment, it yet has 
several challenges in cytokine release syndrome (CRS) and off-target effects in 
subsequent studies and clinical trials (Lee DW et al., 2015; Sun et al., 2018). Moreover, 
the most severe problem for immunotherapy lies in its long time and much painful 
treatment when extracting and implanting immune cells from the patient’s Lymph node 
or spinal cord (Verdijk et al., 2009). The main reason for doing this comes from the fact 
that the gene editing and genetic engineering tools all current therapeutic methods used 
are based on viral vectors. This viral vector transduction requires collected cells to be 
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treated in vitro for 24 to 48 hours before transfection, cells cultured in vitro, and another 
72 to 96 hours following transfection with (Kochenderfer et al., 2010). Due to these 
unavoidable requirements, the genetic modification process of immune cells can last 
about 120 to 150 hours in vitro. Therefore, two Lymph node or spinal cord surgeries are 
necessary for the whole therapy period which makes the patient suffer much pain. 
Therefore, scientists are still looking for alternative ways to simplify the process of gene 
transfection, which are expected to save time for genetic engineering, reduce patient 
suffering, and ensure reasonable transfection efficiency and cell viability. 
2.4 Gene Transfection Methods 
2.4.1 Virus Vectors in Gene Delivery 
Viral transduction is a eukaryotic gene transfer tool that is widely used in gene 
therapy (Figure 2-6). Viral vectors used in viral transduction include retroviral vectors, 
adenoviral vectors, lentiviral vectors, and herpes simplex virus vectors. Viral vectors can 
infect target cells efficiently because they can encapsulate and protect their genetic 
probes to effectively escape the lysosomal retention and deliver the carried gene probes 
to the nucleus of target cells via microtubule transport. Compared with other methods, 
gene delivery via viral vectors has unique advantages: (1) they have a broad host which 
can infect both dividing and non-dividing cells and a high transfection efficiency for cells 
that are difficult to transfect, such as primary cells, stem cells, and undifferentiated cells; 
(2) viral vectors have a specific resistance to transcriptional silencing and can obtain 
sustained and stable expression in the target cells; (3) viral vectors can be inserted into 
tissue-specific promoters and enhancers to increase the transcriptional targeting 
efficiency of specific gene probes, allowing targeted genetic probes to be expressed in 
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specific cells or tissues. Because of these major advantages, viral vectors have become 
widely adopted as a useful transfection tool to verify the function and effectiveness of 
foreign genes in gene therapy.  
Despite their many advantages, viral vectors, however, also have some 
disadvantages that cannot be ignored. First, the packaging capacity limitation of a virus 
cassette was considered to be smaller than 5 kbps. This makes the viral vectors very 
difficult or impossible in some cases to encapsulate large or multifunctional plasmids 
(Wu et al., 2010). Secondly, viral vectors have biosafety issues based on the clinical data 
published in The New England Journal of Medical in 2002. After a successful practice on 
the use of genetically manipulated hematopoietic stem cells to treat X-linked severe 
combined immunodeficiency (SCID-X1) (Hacein-Bey-Abina et al., 2002), five of the 
nine patients who received the treatment were diagnosed with leukemia after one year 
(Hacein-Bey-Abina, 2003; Hacein-Bey-Abina et al., 2003; Mccormack & Terence H, 
2004). Due to the integration of viral gene recombination, the human genes LMO2 (LIM 
Domain Only 2) were abnormally activated. Although the toxic genes in our commonly 
used viral vectors have been replaced by exogenous target genes, viral vectors still have 
potential biological dangers as the primary source of lentiviral vectors is HIV while its 
natural host is human. In current clinical trials, the use of gamma retroviral vector gene 
transduction has a latency period of about three years, and the relative safety of HIV-
derived lentiviral vectors has not been followed up for a long time. So, more patients are 
needed for this type of safety study and long-term risk of virus transduction for therapy is 
still unclear (Pauwels et al., 2009). 
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Figure 2-6: Virus gene vector types. (Worgall & Crystal, 2014) 
2.4.2 Non-Viral Vectors in Gene Delivery 
Because of the safety concerns and/or potential risks of the viral vector, non-viral 
vectors drew great attention in gene delivery. Since 1987, many types of cationic 
liposomes have been synthesized and tested for their performance in the non-viral 
delivery of therapeutic probes (Felgner et al., 1987; Zhi et al., 2013). Cationic liposomes 
are composed of two 12-18 hydrocarbon chains, two separated ends of which are 
hydrophobic carbon molecules while the other end is a hydrophilic N+ cationic group. 
Similar to what present in the cell membrane, cationic liposomes can form a double-layer 
structure in water to bind and encapsulate genetic probes such as DNA and RNA as gene-
lipid complexes, or lipoplexes (Zhi et al., 2010). These lipoplexes are formed by 
electrostatic interactions between negatively charged genes and positively charged 
cationic liposomes. The mechanism of cationic liposome-mediated gene transfection can 
be briefly described as the positive charges on the surface of cationic liposome that 
promote lipoplex absorption on the negatively charged cell membranes via electrostatic 
interactions; the lipophilicity of liposome allows the gene-lipid complexes to enter cells 
and form endosomes by intracellular endocytosis and cell membrane fusion; the genetic 
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probes are then released into the cell cytosol and further into the nucleus to start 
transcription (Zabner et al., 1995) (Figure 2-7). However, although the lipoplex delivery 
method has several advantages such as a simple synthetic process, no immunogenicity, 
and fast degradation in cells, this nonrival gene delivery method is much less effective 
than its viral delivery counterparts and show more or less toxicity. For example, cationic 
liposomes can activate caspase such as caspase-3 and caspase-9 which are the key 
enzymes in the process of cell apoptosis and eventually cause cell death. Such cell 
apoptosis potential increases as more cationic liposomes accumulate in cells and the 
activity of caspase enzymes becomes more significant (Zuhorn et al., 2002). 
 
Figure 2-7: Schematic of the Cationic Liposomes principle. (Behfar, 2013) 
The calcium phosphate transfection method is another gene transfection method 
that has been used since the early 1970s (Graham & A.J., 1973). Briefly, the target DNA 
probes are mixed with calcium chloride in phosphate buffer to form a calcium-
phosphate–DNA co-precipitates. The co-precipitates are then co-cultured with cells and 
the calcium-phosphate-DNA co-precipitates enter cell cytoplasm by endocytosis. The 
major components required for this transfection method are readily available and 
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inexpensive. However, the transfection efficiency of this method is susceptible to pH 
value, temperature, and buffer ion concentration in the transfection environment 
(Chalberg et al., 2005). Moreover, like lipoplex, it shows toxicity to various cells. So 
many types of primary cells, its application range is quite limited compared to other 
transfection methods (Zauner et al., 1996). 
Other than the chemical non-viral delivery method, physical approaches such as 
gene gun and electroporation (which is introduced in the next section separately) were 
also explored for potential gene delivery. Gene gun or particle bombardment method is a 
mature gene delivery method. In 1987, the earliest gene gun technology was developed 
by John C. Sanford (Sanford et al., 1987). Gold or tungsten particles were used in this 
method as a gene vector, which was sent to cells by the power of compressed nitrogen, or 
helium gas (Oard et al., 1990; Sautter et al., 1991) (Figure 2-8). In gene gun, target 
genetic material is attached to those inorganic nanoparticles and is directly ingested into 
animal or plant cells, or organelles that need to be engineered to achieve gene transfer. As 
a purely physical method, it can perform gene transfer for any target cell with no strict 
requirement on the size of genetic probes and no long-term unpredictable safety concerns 
(Wang & Yu, 2003). However, compared to the other gene delivery methods, the number 
of cells that can be treated by this method is very limited and the gene gun equipment and 
bullets are expensive (Davies, 2004). 
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Figure 2-8: Schematic of the working principle of the Gene Gun. (Muhammad, 2019) 
2.5 Electroporation in Molecules Delivery 
2.5.1 Introduction 
In the past few decades, electroporation has been widely employed as the major 
physical method to facilitate intracellular delivery of nucleic acids (such as DNA 
plasmids, mRNA, siRNA, and microRNA) besides its applications in other different areas 
like drug delivery (Figure 2-10). Electroporation has outstanding performance in many 
aspects, such as reasonable transfection efficiency, short transfection time, safety, easy 
operation, and non-restrictions on the type of cells and genetic probes. 
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Electroporation research started from the late 1950s and showed that the cell 
membrane would reversibly breakdown when a pulsatile electric field was applied to 
cells with appropriate pulse duration (Stämpfli & M. Willi, 1957). In 1972, the name 
“electroporation” appeared in a report that showed the permeability of the cell membrane 
would be increased upon applying an electric field (Turnbull et al., 1973). Neumann and 
Zimmermann first designed it as an electrically mediated gene delivery system in 1982 
(Neumann et al., 1982). Since then, electroporation has been redesigned and optimized 
many times prior to serving as a mature gene delivery tool today. 
During electroporation, cells are placed in an external electric field for a short 
period. Under the influence of the transmembrane potential, the conductivity and 
permeability of the plasma membrane of the subjected cells are increased, and the 
charged foreign materials are allowed to enter the cell cytoplasm (Rols et al., 1998). Due 
to the massive resistance of the phospholipid bilayer of the cell membrane, the voltage 
from the electric pulse is imposed mainly on the cell membrane, other than the nuclear 
membrane or membrane for organelles inside cells. Therefore, the electric field allows 
DNA and other substances to cross the cell membrane and stop nearby in electroporation. 
Subsequent transport of these substances inside the cell, for example, their entry to the 
nucleus, still relies on other mechanisms (Weaver, 2003).  
Several hypothetical mechanisms were proposed to explain how a pulsatile 
external electric field would temporarily improve the permeability of cell membranes 
during electroporation. It is generally believed that the transmembrane voltage acting on 
the stratum corneum can form transient aqueous passageways across the cell membrane 
under short electrical pulses, which causes structural rearrangements of the membrane 
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phospholipids. Hydrophilic pores are formed in the lipid bilayer of the cell membrane, 
which allows drugs or gene probes to travel across the cell membrane directly in a short 
time (Weaver, 1995) (Figure. 2-9). After the treatment, the hydrophilic pores on the cell 
membrane will disappear and the cell membrane will be resealed. However, if the electric 
field energy becomes too high and the exposure time becomes too long, the cell 
membrane will be irreversibly damaged, which will eventually lead to cell death (Han et 
al., 2003; Wang & Chang Lu, 2006; Bao et al., 2008). 
 
Figure 2-9: (a) Normal cell membrane, (b) A cell excited by short electrical pulse 
resulting in irregular molecular structure, (c) The membrane being notched, (d) The cell 
with a temporary hydrophobic pore, and (e) The cell with a hydrophilic pore after 




Figure 2-10: Electroporation of a cell may be reversible or irreversible. Irreversible 
electroporation can lead to cell apoptosis and be used to treat cancer. Reversible 
electroporation can be optimized for the introduction of small and large molecules, the 
fusion of cells, and the insertion of proteins into the cell membrane (Matej & Damijan, 
2010). 





𝑟𝐸𝑒𝑥𝑡 cos 𝜃 [1 − 𝑒𝑥𝑝 (−
𝑡
𝜏𝑚
)]               Eq. 2-1 
where 𝛥𝑉 is the transmembrane potential, 𝑟 is the radius of the cell, 𝐸𝑒𝑥𝑡 is the 
electric field strength, 𝜃 is the angle between the electric field direction and the 
membrane surface, 𝑡 is the time after the electric pulse onset, 𝜏𝑚 is the membrane 
charging time constant, given by:      
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                 Eq. 2-2 
where 𝜎𝑖 is the conductivity of the cytoplasm, 𝜎𝑚 is the conductivity of the cell 
membrane, 𝜎𝑒 is the conductivity of the extracellular medium, 𝜀𝑚 is the dielectric 
permittivity of the membrane, and 𝑑 is the cell membrane’s thickness (Schwan, 1957; 
Kotnik et al., 2012; Gimsa & Derk, 2001). 
2.5.2 Electrical Factors in Electroporation 
According to the above equation (Eq. 2-1; Eq. 2-2), we can identify several 
factors that influence the electroporation process: 
Cell membrane conductivity and medium conductivity are two vital factors. 
According to Eq. 2-2, we can find out that the cell membrane conductivity and medium 
conductivity determine not only the transmembrane potential but also the charging rate of 
the transmembrane potential. If the cell membrane and medium conductivity are high, the 
system resistance is small. Under a specific voltage condition, the current will increase, 
and more heat will be generated, which will lead to a decrease of cell viability. For 
bacterial cells, electroporation systems require low-conductivity, high-resistance media to 
prevent arcing at high voltages during the process, because bacterial transfection always 
requires high voltages. However, for mammalian cells, the voltage required in the system 
is relatively low, so a medium with relatively high conductivity and low resistance is 
needed to increase the transfection efficiency of electroporation. 
Pulse waveform type also affects the efficiency of electroporation. There are two 
main types of pulse waveforms: square wave pulse and exponentially decaying wave 
pulse. A square wave pulse refers to the voltage instantly rises to a preset voltage and is 
maintained at that level for a period and then the discharge is terminated immediately. 
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Generally, square wave pulses are selected for the transfection of mammalian cells. The 
exponentially decaying wave pulse refers to the charge of a capacitor first, followed by 
the discharge of the capacitor completely so that the voltage decays exponentially. This 
type of pulse is suitable for bacteria, yeast, and insect cells. 
Pulse time (duration) is another important factor. The selection of the pulse time 
mainly depends on the pulse waveform. In the square wave pulse, the pulse time can be 
set directly. In the exponentially decreasing wave pulse, the pulse time refers to the time 
it takes for the voltage to decay to one-third of the initial voltage (i.e., the maximum 
voltage), which is equal to the product of the capacitance (C) and resistance (R). In the 
parameter optimization process, increasing the pulse voltage should be accompanied by 
the reduction of the pulse duration to balance the transfection efficiency and the viability 
of the cells. 
2.5.3 Non-Electrical Factors in Electroporation 
Besides the several electrical signal related factors mentioned above, the 
electroporation result is also determined by some other factors. 
(1) Cell size. According to the first equation (Eq. 2-1), we can see that the cell 
radius (or cell size) is also a critical factor. A giant cell gains a high transmembrane 
potential, and similarly, a small cell receives a low transmembrane potential. This 
coefficient is more difficult to control during the actual electroporation process because 
the cell size varies wildly. Even in the same cell type, the cell size is the same under 
different division stages or nutritional conditions. Current commercial electroporation 
instruments can only set one parameter of the electric field to satisfy the appropriate 
transmembrane potential for a certain type of size in their average size during an 
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electroporation process. Therefore, the electroporation results are often not very 
consistent when the cell is significantly different from batch to batch. 
(2) Cell state. The cells used for an electroporation test are generally selected 
in the logarithmic growth phase (within 15 generations, two days after subculturing). Due 
to the vigorous cell division in the logarithmic growth phase, the surface structure is 
looser than stable phase cells. After electroporation, the cell membrane has a strong 
recovery ability, and the followed the mitotic phase of cells is more likely to accept the 
foreign gene probe.  
(3) Genetic probe. The size of the gene probe affects its cell uptake efficiency 
during electroporation. Generally, small fragments of probes are naturally easier to get 
introduced in cells than large fragments. Also, the transfection efficiency increases for 
samples with higher probe concentration within a specific range. However, after reaching 
the maximal value, further increase of the probe concentration actually would drag down 
the transfection efficiency and cell viability gradually. This phenomenon might be caused 
by the existence of saturation of genetic probes in cells. Further high concentration would 
change significantly the osmotic pressure or other conditions inside cells that affect the 
functions and viability of cells. As a result, the overall transfection efficiency decreases. 
2.5.4 Nanosecond Pulses Electroporation 
The electrical pulses used in the ordinary commercial electroporation system are 
millisecond electrical pulses. Millisecond electrical pulses can cause an imbalance in the 
electric charge on both sides of the cell membrane and induce the bilayer of 
phospholipids to move, thereby forming hydrophilic pores (Weaver 2000). Later, it was 
discovered that during the electroporation process, when the duration of the electrical 
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pulse was reduced from milliseconds to nanoseconds, and the electric field strength 
increased to 100KV/cm, it will cause a range of different cellular responses inside the 
cell, such as the nucleus, mitochondria, and endoplasmic reticula(Schoenbach et al., 
2001; Schoenbach et al., 2004), though there is no obvious electroporation hydrophilic 
pore on the cell membrane surface. Many micronuclei will be produced in cells and cells 
will be induced to enter programmed death. This phenomenon is defined as Intracellular 
Electromanipulation (IEM) (Beebe et al., 2002). Some explanations suggest that IEM 
occurs because nanosecond electrical pulses can generate large transmembrane potentials 
on the membrane of organelles. When the transmembrane potential of organelle 
membranes exceeds a critical value, electroporation will occur on these organelles’ 
membrane. The nanosecond electrical pulse produces a small transmembrane potential on 
the outside cell membrane so the cell membrane may become fragile, but no obvious 
electroporation occurs (He et al., 2017; Breton & Lluis, 2012; Qi et al., 2014). 
In 2008, Vermier found that nanosecond pulses can promote the release of 
calcium ions in cells. He used a calcium-sensitive fluorescent material, calcium green to 
label chromaffin cells, and then treated them with nanosecond pulses. He found that the 
fluorescence intensity of the treated cells was enhanced. This proves that nanosecond 
pulses can increase the flow of calcium ions. In 2004, Chen used the fluorescent dye 
Acridine Orange (AO) to label HL-60 cells and then treated them with nanosecond 
electric pulses. They observed through confocal microscopy that the fluorescence 
intensity of the nucleus of cells was reduced after treated with nanosecond electric pulses. 
This shows that the number of AO-DNA complexes in the nucleus is reduced. Chen 
explained that the nanosecond pulses caused an increase in the permeability of the 
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nuclear membrane, which caused the AO-DNA complex to flow out of the nucleus (Chen 
et al., 2004).  
A few attempts later looked into the potential of nanosecond pulses for gene 
delivery, in principle, could improve the permeability of cell nuclear membrane (Beebe et 
al., 2006; Chopinet et al., 2013; Ruzgys et al., 2018). However, owing to its ultra-short 
pulse duration and ineffectiveness on breaking down the cell plasma membrane, 
disappointing gene transfection results are mostly found unless extremely high field 
strength was applied in some cases (Ford et al., 2010). But this is often tied with low cell 
viability because of the severe side effects associated with the applied high electrical 
voltage (Pakhomoya et al., 2011; Kim et al., 2007; Movahed & Li, 2010; Wang et al., 
2009; Chang et al., 2016). DNA transfection with nanosecond pulse treatment still faces 
substantial challenges to receive both desirable gene expression and cell viability. 
2.5.5 Micro-/Nanofluidics Based Cell Electroporation 
The high-voltage pulses in electroporation, though effective in improving the cell 
membrane permeability and probe uptake, inevitably leads to severe side effects 
detrimental to later cell survival (Movahed & Li, 2010; Kim et al., 2007; Wang et al., 2009) 
such as Joule heating and pH change to nearby treated cells. The available protocols of the 
electroporation are therefore established by trial-and-error by balancing acceptable 
transfection efficiency and cell viability. Many new electroporation setups with micro-
/nanoscale features have been developed to overcome these challenges. In these new 
systems, either electrode pairs are closely patterned (Lee & Tai, 1999; Lin et al., 2001; Lu 
& Jensen, 2005; Guignet & Tobias, 2008; Dalmay et al., 2011; Garcia et al., 2016) or 
micro/nanofluidic channel constriction are integrated (Kurosawa et al., 2006; Wang & Lu, 
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2006; Khine et al., 2005; Huang & Boris, 2001; Shin et al., 2004; Fox et al., 2006; Lee et 
al., 2009; Kim et al., 2011).   
In this way, a very low voltage across the electrode pair can generate pulses with 
high enough field strength, such as 500-1000V/cm, to accomplish cell membrane 
breakdown. The introduction of microfluidic components in these systems can also 
mitigate the adverse effects of traditional commercial electroporation systems such as 
water electrolysis, bubble formation, poor electrochemical activity, and Joule heating, all 
associated with the high-voltage pulses employed in traditional electroporation. In 
addition, the low voltage may also minimize the extra damage to the treated cells and 
prevent them from losing too many intracellular components (Huang & Boris, 1999; 
Valero et al., 2008; Shin et al., 2004). Besides the major advantages of reducing the pulse 
voltage, microfluidics-based electroporation offers new advantages over the commercial 
systems, namely in situ monitoring of intracellular content transport and electroporation 
dynamics at the single-cell level. Furthermore, it could also provide flexible treatment 
throughput on cell numbers to satisfy various demands from different applications on 
electroporation. For example, the transfection of a single cell or a few cells is suitable and 
sufficient for cell biology analysis and transgenesis. But for therapeutic practice, larger-
scale transfection with a cell number in the order of 105-109 is required. As for cell-based 
bioreactors to produce therapeutic protein, the preferred cell numbers are generally in the 
billions or higher. Several research groups have demonstrated that flexible scale cell 
transfection in low-voltage, microfluidic electroporation by designing microchannel 
arrays (Munce et al., 2004; Khine et al., 2005; Khine et al., 2007; Ionescu-Zanetti et al., 
2008; Kim et al., 2008). The use of fluid systems not only allows continuous processing 
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of many cells for high-throughput electroporation but also helps to change the 
permeability of the cell membrane and improve the performance of electroporation 
(Wang et al., 2010). 
Although these micro-/nanofluidic-based cell electroporation systems show 
great potentials to advance future life science and medical research, their delivery 
performance and reliability have not yet been comprehensively examined. Most of them 
stay on the quick concept demonstration stage to deliver fluorescence dyes, small 
chemicals, and at most, DNA plasmids or RNA probes in model cell lines of mammalian 
cells, yeast, and bacteria. Data on valuable therapeutic probes and clinically important 
primary cells or patient samples still largely lacks. In addition, most of these micro-
/nanoscale systems have relatively complicated operation procedures, not easy for end-
users other than trained engineers such as biologists and medical doctors to operate and 
adapt to their current setup and procedures. More efforts should be given to clear these 
barriers before their applications in clinic practice, besides the general expectation for 
any new therapeutic methods on higher delivery efficiency with precise treatment, quick-
expression, and the consequent appropriate cell viability for those cells and probes. This 
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Electroporation is widely used for DNA and RNA probe transfection. Hydrophilic 
pores are formed on the lipid bilayer of a cell membrane when an appropriate electric 
pulse is imposed on, which allow drugs or gene probes to travel across in a short period 
before the resealing of the cell membrane (Weaver, 1995). It has advantages like quick 
delivery process, acceptable cell viability and gene transfection rate, and no limitation to 
cell types or transfection agents. The electrodes used in conventional electroporation 
systems from Harvard Apparatus, Bio-Rad, Eppendorf, Mirus Bio are aluminum parallel 
electrodes on two sides of a cuvette. Electric pulses with a field strength of several 
hundreds to thousands and application duration of milliseconds are applied between these 
two electrodes to accomplish breakdown of the cell membrane. However, this type of 
electroporation configuration ignores the local electrical variations on individual cells of 
a large population, leaving many factors uncontrolled. Based on Equation 2-1, besides 
the electric field strength, the needed transmembrane potential is also related to the size 
of the treated cell and the conductivity of the electroporation medium. Nevertheless, the 
simple parallel-plate plain electrode setup is currently available electroporation systems 
cannot fix these problems. 
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In this chapter, we introduce a new electrode configuration and integrate it into a 
new electroporation system, namely Carbon Nanotube Micropillars Electroporation 
(CNTPs) system. In this system, carbon nanotube coated polymer micropillar array is 
fabricated to implement size-specific electroporation. These carbon nanotubes (CNTs) 
offer the needed electrical conductivity of the micropillar array structure while the 
polymer base holds CNTs to avoid falling off the electrode surface during the pulse-on 
time to cause additional toxicity to the treated cells. CNTs also offer comparable 
conductivity as a metal electrode while eliminating the potential introduction of 
unwanted metal ions in the electroporation medium, which are found toxic to cells. The 
nanoscale structure on these CNT nanoelectrodes can highly focus the electric field in 
many nanoscale locations, thereby achieving uniform electroporation on cells of different 
sizes. We evaluated the transfection enhancement of this CNT pillar array nanoelectrode 
with reporter DNA plasmids (pMaxGFP), siRNA, and microRNA probes. Human 
leukemia cells (i.e., K562 cells) were tested to demonstrate its effectiveness.  
3.2 Materials and Methods 
3.2.1 Materials and Reagents 
DNA plasmids probe with pMaxGFP reporter genes were purchased from Lonza, 
Inc. siRNA used for silencing pMaxGFP were synthesized by Thermo Scientific 
(Pittsburgh, PA) and the sequences were as follows: siRNA for GFP silence, sense strand, 
5-CGCAUGACCAACAAGAUGAUU-3; antisense strand, 5-
UCAUCUUGUUGGUCAUGCGGC-3. All other cell culture reagents were purchased 
from Life Technologies (Carlsbad, CA), and all the chemicals were purchased from 
Sigma-Aldrich unless specified. 
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3.2.2 Cell Culture 
K562 cells (ATCC, CCL-243) and CT26.WT cells (ATCC, CRL-2638) were used 
in the electroporation test. These cells were cultured in RPMI 1640 medium 
(supplemented with 10% FBS, 1% L-Glutamine, and Penicillin/streptomycin). All 
cultures were maintained at 37 ℃with 5% CO2 and 100% relative humidity. 
3.2.3 Carbon Nanotube Micropillar Array Electrode Fabrication 
A piece of SU-8 Micropillars Array on Si wafer was cleaned by acetone, IPA and 
DI water and dried in an oven at 50 ℃, as the master mold. After that, a mixture of 
PDMS precursor with the curing agent at a 10:1 ratio was cast on the surface of the mold. 
After 4 hours of curing at 60 ℃, the cross-linked PDMS layer was carefully cut and 
peeled off the SU-8 master mold. Carbon nanotubes (CNTs) were then applied to the 
PDMS mold surface and rubbed to get a thin layer of CNTs coated on the PDMS mold.    
Another blank Si chip was cleaned by acetone, IPA, and DI water and dried by a 
nitrogen gun. After that, a thin layer of SU-8 2002 photoresist was then coated on this 
cleaned Si chip. The CNTs coated PDMS mold was then pressed into the SU-8 layer on 
the Si chip. The whole pieces (PDMS, CNTs, SU-8 layer, and Si chip) were then 
sandwiched between two pieces of glass slides using document clips. Because uncured 
SU-8 photoresist is stickier than the PDMS mold surface, the pressing force pushes CNTs 
into the SU-8 coating layer, so makes the microwell pattern on PDMS mold (the negative 
replica of micropillar array from the Si master mold). After exposed under a UV light for 
5 min, SU-8 2002 layer are cross-linked and was further solidified with hard baking at 
100 ℃ for 1 hour. Finally, the PDMS mold was carefully removed from the silicon chip, 
leaving SU-8 micropillars with CNTs coated on their surface top. In CNT bundles, the 
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bottom part was embedded in SU-8 and the top part exposed, forming small bumps at the 
nanometer scale on the surface of micropillars as nanoelectrodes. When cells are placed 
on them, these protruded CNTs will contact and delivery electric pulses on the cell 
membrane. 
3.2.4 CNTPs Electroporation Setup and Operation Procedure 
Cells were first centrifuged and re-suspended in fresh OPTI-MEM I (a serum-free 
medium) at a density of 2.5×107 cells/ml. Plasmid DNA (pMaxGFP) of 1 µg was then 
added in each electroporation sample (total volume of each sample is 5 µL). These 
samples were loaded onto the CNTPs surface (CNTPs was considered as a positive 
electrode). A piece of ITO-coated Glass (ITO Coated Glass was considered as a negative 
electrode) with a PDMS gasket (~200 µm thickness) was then placed from the top of a 
cell sample to hold the electroporation solution. Electric pulses were added on these 
samples with the following pulse conditions: 2.5 kV/cm of the pulse strength and single 
10-ms pulse with a rectangular pulse profile. After electroporation, the ITO-coated Glass 
was removed, and cells were washed off from the CNTP electrode. They were collected 
and transferred to 12-well plates and cultured for 24 hours at 37 ℃ with 5% CO2 and 
100% relative humidity before further analysis. 
3.2.5 Transfection Efficiency and Cell Viability 
The expression of pMaxGFP plasmids is evaluated both qualitatively by 
visualizing cells with green fluorescence within some representative areas under an 
inverted fluorescence microscope (Olympus, Japan) and quantitatively by counting cells 
using a flow-cytometer (CytoFLEX PN B49006AE) with a laser wavelength of 495 to 
519 nm. The results were analyzed with Cytexpert software, and 10,000 events were 
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counted for each sample. The transfection efficiency of pMaxGFP is defined as the 
number of cells emitting fluorescence signal to the total number of cells in a sample 
(gated fluorescence signal of GFP). 
The cell viability was evaluated by an MTS cell proliferation assay (Promega, 
Madison, WI). Briefly, 100 μL cells 24 hr post-electroporation from each sample were 
transferred to a 96-well plate, and CellTiter 96 AQueous One solution (Promega, 
Madison, WI) of 20 μL was added to each well, and all samples were incubated at 37 ℃ 
for 1 hr. Absorbance was measured at 492 nm on an automated plate reader (Elx 800, 
Biotek, VT). Data points were represented as the mean ± standard deviation (SD) of 
triplicates unless otherwise indicated. The cell viability is calculated as the absorbance 
signal ratio of an electroporated cell sample to that of the negative control cell sample in 
MTS assay, after extracting the absorbance background from the media. 
3.2.6 Determination of MicroRNA Delivery Efficiency 
The miR-29b delivery efficiency was evaluated from two aspects: first, the 
expression level of miR-29b. Second, the downregulation performance or expression 
level of target genes, including CDK6, DNMT38B, and MCL1. To measure the 
expression levels, the total RNA was first reverse transcribed into cDNA, and a Realtime-
PCR was conducted. The expression level was determined by the ΔΔCt method and 
normalized to endogenous controls. 
3.2.7 Total RNA Extraction 
Total RNA was extracted using TRIzol reagent (Life Technologies, Carlsbad, 
CA). Cells were harvested by centrifugation and the culture medium was removed. After 
that, 250 µl TRIzol reagent was added to each sample (containing approximately 8 to 
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10x105 cells). Samples were lysed by pipetting several times and incubated for 5 min at 
room temperature. The nucleoprotein complex was dissociated completely. Chloroform 
of 125 µl was added to each sample and the tubes were shaken vigorously for 15 s 
followed by 3 min incubation at room temperature. Then, all samples were centrifuged 
with 12,000 rpm for 15 min at 4 ℃ to separate into a colorless upper aqueous phase, 
interphase, and a lower red chloroform phase. The upper aqueous phase was transferred 
into new tubes by gentle pipetting without drawing any of the interphases, and 500 µl 
100% isopropanol was added into each of aqueous phase tubes, followed by 10 min 
incubation at room temperature. The samples were centrifuged at 12,000 rpm for 10 min 
at 4 ℃ and the supernatant was discarded. To wash the RNA pellet, 200 µl 75% ethanol 
was added into each tube and samples were vortexed briefly and centrifuged at 7500 rpm 
for 5 min at 4 ℃. After removing the supernatant, the RNA pellets were air-dried for 5 to 
10 min. 20 µl RNase-free water was then added into each tube and all samples were 
incubated at 60 ℃ for 10 min. Then the RNA samples were ready for reverse 
transcription. 
3.2.8 Reverse Transcription PCR 
The Taqman® microRNA Reverse Transcription Kit (Life Technologies, 
Carlsbad, CA) was used for microRNAs reverse transcription. The reagents were first 
allowed to thaw on ice. The total volume of 15 µl reaction was prepared in a 
polypropylene tube, including 0.15 µl dNTP mix (100 mM total), 1 µl MultiscribeTM RT 
enzyme (50 U/µl), 1.5 µl 10X RT PCR buffer, 0.19 µl RNase inhibitor (20 U/µl), 4.16 µl 
nuclease-free water, 3 µl primer and 5 µl RNA sample (1000 ng). The thermal cycler was 
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programmed as follows: 30 min at 16 ℃, 30 min at 42 ℃, 5 min at 85 ℃ and hold at 
4 ℃. 
3.2.9 qRT-PCR Amplification 
The resulting cDNA from reverse transcription reaction was amplified by qRT-
PCR with TaqMan™ Gene Expression Master Mix (Thermo Scientific, Pittsburgh, PA). 
The total volume of 20 µl reaction was prepared in a polypropylene tube, including 10 µl 
TaqMan™ Gene Expression Master Mix, 1 µl 20 X TaqMan® assay and 9 µl cDNA 
template. The thermal cycler was programmed as follows: 10 min at 95 ℃ for 
polymerase activation, then 40 PCR cycles with 15 seconds at 95 ℃ for denaturing and 1 
min at 60 ℃ for annealing. The relative gene expression was determined by the ΔΔCt 
method. The mature miR-29b expression was normalized to endogenous control RNU48 
and relative to the untreated control cells. The expression of CDK6, DNMT3B, and 
MCL1 mRNAs was normalized to endogenous controlled GAPDH and relative to the 
untreated controlled cells. 
3.3 Results and Discussion 
3.3.1 CNTs Modified Micropillars 
The motivation of creating micropillars on the electrode surface is to treat 
different sizes of cells at the same time in the same condition. In other words, the cells 
cover more of micropillars that received the focused electric field on more spots of their 
cell membrane. We designed and fabricated CNT coated micropillar arrays with each 
micropillar having a diameter of 2 µm and height about 2 µm, as shown in Figure 3-1(a) 
of the low magnification SEM images of micropillars. Figure 3-1(b) focuses on a single 
micropillar, Figure 3-1(c) shows its top with many CNTs protruded on the surface, and 
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Figure 3-1(d) gives schematically an overall view on CNTs coated micropillar array 




Figure 3-1: SEM images of CNTs coated micropillar electrode (a) 8K magnification 
of micropillar array; (b) single pillar at 30K magnification; (c) the top surface of a 
micropillar at 100K magnification; (d) schematic of an overall CNTs coated 
micropillar electrode. 











3.3.2 CNT & CNTPs Enhancement on Gene Transfection 
In this CNTP electrode, CNTs are employed to provide more electroporation spots 
on the cell membrane with nanoscale resolution. Because of their excellent conductivity, 
CNTs coated on the SU-8 layer, which included the exposed part and embedded part, 
make the micropillar conductive enough to serve as an electrode. The exposed part of the 
CNTs on the surface of micropillars further creates much higher focused electric field 
strength on the cell membrane area they face. As those exposed CNT parts disperse 
randomly on the micropillar top, each in the nanometer scale, more electroporation spots 
are generated on the cell membrane when cells approach the CNTP electrode during 
electroporation. With a surface resistance of around 2 MΩ, the CNT coated micropillar 
electrode needs a voltage of around 50 V (8.3 kV/cm) to achieve a high transfection rate 
in k562 after optimization. As a comparison, the parallel-plate plain aluminum electrodes 
in commercial cuvette type systems require 220 V (550 V/cm). Figure. 3-2(a), shows the 
phase contrast and fluorescent images of GFP expression of K562 cells 24 hours after 
transfection with traditional electroporation (designated as msEP) and electroporation 
systems with  CNT coated plain plate electrodes (designated as CNT), and CNT coated 
micropillar electrode (designated as CNTP). The CNT coated plain plate electrodes 
achieves an enhanced transfection of the GFP plasmids about 12% from msEP (31.5% ± 
0.6%), reaching 43.21% ± 3% and a cell viability of 81.43% ± 2% when compared to 
88.72% ± 0.7% from msEP. After introducing the micropillar structure on the electrode 
besides CNT coating (CNTP), the transgene expression of GFP plasmid significantly 
ameliorates to 84.75% ± 1% with the viability of 80.21 ± 1%. Such transfection 
performance differences of CNTPs, CNT, and msEP are caused by the focused pulse on 
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nanoscale spots on the top of the micropillar electrode and the automatic allocation of 
those electroporation spots on cell membrane regardless of the different sizes of cells and 
their random dispersion status on the electrode. In Figure 3-2(b), the left side is the GFP 
plasmid transfection percentage, and the right side is fluorescence intensity. The latter 
represents the average fluorescence intensity in treated cells, which reflects the average 
quantity of GFP plasmids loaded in each cell while the former indicates the percentage of 
cells that have successful GFP plasmid delivery, estimating the number of cells gets 
transfected successfully. Comparing to the msEP, the CNT and CNTPs electrodes 
achieve 6 folds and 22 folds of the transgene expression of GFP plasmids in K562 cells 
when compared with what is achieved in msEP case. The CNTP case enhances a 2.6 fold 
increase in the transfection percentage (i.e., successfully transfected cell number of 
treated cells). 
Such improvement on the transfection quality and quantity with CNTP electrode 
as the result of more nanoscale focused spots on cell membranes contributed from the 
protruded CNTs on the SU-8 pillar surface. Their small cross-section provide a more 
focused pulse while their large quantity splits the electroporation area on the cell 
membrane to many isolated, tiny spots. In this way, the cell membrane could get a large 
area affected by the electric pulses, having hydrophilic pores in many locations, each 
averagely smaller than what occurs in conventional electroporation with plain plate 
electrode. This not only offers significantly increased port number on the cell membrane 
to allow genetic probe transport across the cell membrane but also makes it easier to 
reseal later due to the small pore size in each spot. With a well-patterned micropillar 
array on the electrode, cells of different sizes sitting on the micropillar top receive around 
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the same current density of electric pulses during electroporation. That is, a large cell 
covers more micropillars than a small one and the number of electroporation spots each 
cell receives is determined by the surface area on its cell membrane facing the CNTP 
electrode. In this way, a similar electroporation level is accomplished for cells of 
different sizes in one sample. In Figure 3-3, the flow cytometry dot plot of msEP has 
shown that there is lower transfection on smaller cells while there is higher transfection 
on medium-sized cells. But for electroporation systems with CNT and CNTP electrodes, 
more cells of various sizes get GFP plasmids delivered. GFP positive cells population 
spread towards both large and small cell subgroups significantly.  
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Figure 3-2: The transfection and cell viability of K562 cells in three different cell 
transfection methods with a cell concentration of 107 cells/mL. (a) The phase contrast 
and fluorescent images, (b) quantitative transgene expression, fluorescence intensity, 
and (c) cell viability of samples 24 hrs after transfection. The images are in order of 
msEP, CNT, and CNTPs. The transgene expression is presented as both transfection 
efficiency for the number percentage of GFP positive cells (left group data in panel b) 
and mean fluorescence intensity for average GFP dosage in individual cells (divided by 
a factor of 105, right group data in panel b). The same color codes are applied in panels 
b and c. Significance t-test was performed with n=3 with **P < 0.01) and compared to 





(a)                                     (b)                                            (c) 
Figure 3-3: The flow cytometry dot plots of (a) msEP, (b) CNT, and (d) CNTPs. 
3.3.3 CNTPs Enhanced siRNA Delivery 
To further demonstrate the effectiveness of CNTPs to RNA probe delivery, we 
chose small interfering RNA (siRNA) with sequences that could specifically silence the 
expression of GFP. Their knockdown efficiency was evaluated by co-transfecting with 
pMaxGFP plasmids. As shown in Figure 3-4, apparent suppression of GFP expression is 
observed when co-delivering pMaxGFP and their corresponding siRNA of 5 pmol to 
K562 cells in both commercial electroporation system and CNTPs. More GFP expression 
was turned off by CNTPs, with an additional ~38% drop than that in BTX. With 30 pmol 
siRNA, the downregulation of pMaxGFP plasmids by CNTPs reaches ~45% further than 
that in msEP (Figure 3-4). It is worth to point out that as co-transfection of plasmids and 
siRNA is used here, the delivery enhancement on the targeting reporter gene and its 
corresponding siRNA occur simultaneously in CNTPs. It must turn off more proteins 
than the msEP system to reach a similar protein expression level. In other words, 38% or 
45% additional downregulation accomplishment comes from a much higher initial GFP 
expression level for CNTP electroporation than what occurs in the msEP system.  
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Figure 3-4: The Transfection efficiency of siRNA (5pmol and 30pmol) along with 
pMaxGFP plasmids co-transfection of K562 cells in two different cell transfection 
methods with a cell concentration of 107 cells/ml. 
3.4 Conclusions 
We developed a Carbon Nanotube Micropillars Electroporation system (CNTPs) 
and evaluated its contributions to the delivery efficiency of DNA and RNA probes with 
both adherent and suspension cells. With the Carbon Nanotube Micropillar Array 
Electrodes, many cells were treated regardless of their various sizes by focus pulse 
strength and the localized portion to the cell membrane. The delivery efficiency and cell 
viability were evaluated with leukemia cells (i.e., K562).  Although more DNA and RNA 
























probes were taken up by cells under the influence of CNTPs, no significant cytotoxicity 
was produced compared to the commercial electroporation system. In general, the CNTPs 
showed 2~3 folds improvement on the transfection efficiency of the plasmid DNA 
probes, while the cell viability shows no significant difference when compared with the 
commercial electroporation system. As for the enhancement of RNA probe delivery, 
there is a 2.5 folds improvement shown on the gene downregulation.  According to the 
results of the flow cytometer, the improvement of transfection efficiency comes from the 
fact that a broad size population of cells got successfully transfected while, in the 
commercial electroporation system, only certain subpopulations receives most 
transfection efficiency. This success may serve as a safe and effective non-viral gene 






MICROFLUIDIC ELECTROPORATION COUPLING PULSES OF 
NANOSECONDS AND MILLISECONDS TO FACILITATE RAPID 




Electroporation works by applying short, high-voltage electrical pulses across the 
cell membrane to make it transiently permeable to exogenous cargos (Gehl, 2003). 
Although sub-microsecond charging time is enough to temporarily surpass the cell 
membrane capacitance, the actual pulse duration in standard electroporation practice is 
within sub-millisecond to millisecond range to allow effective payload delivery while 
ensuring the successful recovery of the integrity of cell plasma membrane and the 
survival of the treated cells. Nevertheless, owing to its balance of operation simplicity, 
transfection effectiveness, and broad allowance of the probe or cell types, such reversible 
electroporation systems are often chosen as the preferred delivery approach in the past 
two decades to facilitate cellular internalization of plasmid DNA, oligonucleotides, and 
molecule drugs in many biological and clinical studies (Sowers, 1992; Hu & Li, 2014; 
Yang et al., 2019). Besides such reversible electroporation treatment, ultra-sharp, but 
ultra-short electrical pulses (10 to 300 kV/cm with 10 to 300 ns pulse duration) were 
recently found useful to induce cell apoptosis for cancer treatment (Beebe et al., 2002; 
Garon et al., 2007; Nuccitelli et al., 2009; Perera et al., 2018; Beebe et al., 2003; Davalos 
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et al., 2005). These nanosecond pulses are believed to alter the status of ions (e.g., Ca2+) 
and biomolecules (e.g., phosphatidylserine) around cell plasma membrane or other 
membrane structure of intracellular organelles, either temporarily or permanently 
(Schoenbach et al., 2004; Schoenbach et al., 2001; Silve et al., 2012; Schoenbach et al., 
2001). These intracellular changes could significantly impact the signal pathways inside 
cells, leading to an increase of calcium concentration within cytosol, DNA fragmentation, 
caspase activation, and cell shrinkage (Vernier et al., 2003; White et al., 2004; Chen et 
al., 2004). Therefore, most early studies on nanosecond pulse treatments focus on 
enhancing those irreversible changes in organelles inside treated cells and their 
consequent apoptosis. There are a few attempts later that look into its potential for 
promotion of gene delivery since nanosecond pulses, in principle, could improve the 
permeability of cell nuclear membrane (Beebe et al., 2006; Chopinet et al., 2013; Ruzgys 
et al., 2018). However, owing to its ultra-short pulse duration and ineffectiveness on 
breaking down the plasma membrane, disappointing gene transfection results are mostly 
found unless extremely high field strength was applied in some cases (Ford et al., 2010). 
However, this is often tied with low cell viability for severe side effects are associated 
with the applied high electrical voltage (Pakhomoya et al., 2011; Kim et al., 2007; 
Movahed & Li, 2010; Wang et al., 2009; Chang et al., 2016). DNA transfection with 
nanosecond pulse treatment still faces substantial challenges to receive both desirable 
gene expression and cell viability. 
Speeding up nuclear delivery of plasmids is still highly desired in DNA-based 
gene delivery as genetic probes were found to degrade very quickly even after cell 
internalization (Lechardeur et al., 1999; Vandenbroucke et al., 2007). Unfortunately, 
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available nuclear permeabilizing agents (e.g., trans-cyclohexane-1,2-diol or TCHD) are 
very toxic (Griesenbach et al., 2012). Considering its potential for disrupting the nuclear 
membrane structure (Tekle et al., 2005; Schoenbach et al., 2001), we hypothesize that 
appropriate nanosecond pulse treatment might promote quick nuclear entry of plasmids 
from cell cytoplasm while microfluidics could help suppress its associated negative 
impacts on cells caused by the frequent application of high-voltage, nanosecond pulses. 
Through this work, we demonstrate this concept by coupling appropriate nanosecond 
pulse treatment (designated as “nsEP”) with traditional millisecond standard 
electroporation (designated as “msEP”) to allow cell uptake of plasmid quickly and 
efficiently. A microfluidic configuration is introduced during the nsEP treatment to 
effectively mitigate the side effects induced by electrohydrolysis and Joule heating which 
are commonly seen in the other nanosecond pulse treatments. In our nsEP circuit, the 
nanosecond pulse generation unit is separated from the high-voltage supply unit while 
linked by a MOSFET switch (Figure 4-1a). The rectangular signal from the pulse 
generator periodically triggers the closure of the electroporation circuit through the 
MOSFET switch to allocate high-voltage pulses with nanosecond duration. The 
nanosecond pulse parameters (i.e., voltage, duration, and frequency) can be flexibly 
regulated by adjusting the pulse generator signal. Two Pt wire electrodes are integrated 
on the sidewall of a home-made microfluidic electroporation channel to help shorten the 
response time and lower the electroporation voltage (Figure 4-1b). All these new 
features together enable stable pulse voltage and a well-retained nanosecond pulse profile 
when tuning some pulse parameters in nsEP treatment (Figures 4-1c & d). As some 
oscillations and reflections exist at the pulse profile tail, the pulse duration mentioned in 
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this work is defined as the period from the primary rectangular pulse and the followed 
first spike-wave pulse, as illustrated in Figures 4-1c & d.  
In this new system, nanosecond pulses are first imposed on cells to make the 
nuclear membrane permeable, followed by a standard millisecond pulse treatment that 
breaks down the cell plasma membrane. This allows the target DNA probes to transport 
across both types of membrane barriers quickly to arrive in the nucleus. Different from 
other nanosecond pulse studies with pulse durations of 60 to 300 ns (Sundararajan, 2008), 
we choose slightly longer pulses (400 to 800 ns) in our nsEP treatment so that the 
disruption of the nuclear membrane is more effective. Two separate pairs of electrodes 
are used: one pair of platinum wire-based electrodes serve in nanosecond pulse steps and 
another pair of the standard parallel-plate aluminum electrode in millisecond 
electroporation treatment. Such arrangements help avoid signal entanglement between 
nsEP and msEP treatment steps. The microfluidic configuration in our nsEP treatment 
also helps suppress the gas bubble evolution and consequent damage to cells and/or low 
cell viability that is often observed in electroporation with ultrashort pulses. The 
continuous flow-through operation further allows these treatments to be done to a large 
population of cells in high throughput. The new conceptual system was tested on both 
CT26 (an adherent cell representative) and K562 (a suspension cell representative) cells 
for DNA plasmid transfection. Demonstrated with fast kinetics and significantly 
improved transgene expression without compromise of cell viability, the success of this 
new electroporation system on these representative cell lines as transfection host or 
cancer study models may help advance many biology studies and clinical practice on cell 
function regulation and therapeutic effectiveness verification. 
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4.2 Materials and Methods 
4.2.1 Materials and Reagents 
DNA plasmids with pMaxGFP reporter genes were purchased from Lonza, Inc. 
All other cell culture reagents were purchased from Life Technologies (Carlsbad, CA), 
and chemicals were purchased from Sigma-Aldrich unless specified. 
4.2.2 Cell Culture 
A human chronic myelogenous leukemia (CML) cell line, K562 (ATCC, CCL-
243) and a murine colorectal carcinoma cell line from a BALB/c mouse, CT26.WT cells 
(ATCC, CRL 2638) were used in the electroporation experiment as the representative of 
suspension cells and adherent cells, respectively. These cells were cultured in RPMI 1640 
medium (supplemented with 10% FBS, 1% L-Glutamine, and Penicillin/streptomycin). 
All cultures were maintained at 37 ℃ with 5% CO2 and 100% relative humidity. 
4.2.3 Nanosecond Pulses Electroporation Device Fabrication 
A home-made circuit board was designed to generate the nanosecond pulses with 
different parameters of voltage (V), frequency (HZ), and duration (ns). The circuit board 
includes three separate units, which are connected with an n-channel enhanced radio 
frequency metal-oxide-semiconductor field-effect transistor (MOSFET), as shown in 
Figures 4-1a. The pulse generation unit includes a low-voltage pulse generator (Agilent 
33220A), a resistor load carrier, and a MOSFET switch. The power supply unit has a 
high-voltage DC power supply (KIKUSUI PMC250-0.25A), two resistors, and a 
capacitor (shared with the electroporation unit). The electroporation unit includes a 
capacitor (shared with the power supply unit), a resistor that allocates pulse load, and the 
electroporation device (either cuvette-type from standard electroporation or our home-
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made microfluidic-type one). In this nsEP circuit, the power supply pre-charges the 
capacitor which is used to store energy (when the MOSFET switch is OFF) and supplies 
the needed high-voltage pulses on cells (when the MOSFET switch is ON). The duration 
and frequency of these pulses are decided by the rectangular pulse signal generated from 
Agilent 33220A. By periodically supplying the threshold gate voltage of the MOSFET 
switch, the pulse generator triggers the turn-on moment and duration of the MOSFET 
switch in each pulse. The MOSFET switch manages the open and closure of the 
electroporation circuit so that the pre-charged capacitor from the electroporation unit 
discharges accordingly to allow the high voltage pulse to pass through the electroporation 
device with designed nanosecond width and number. An oscilloscope is used to monitor 
the instant nanosecond pulse profile to ensure its appropriateness. Depending on the 
dimensions of the electroporation device (e.g., a gap size of a standard electroporation 
cuvette or Pt wire electrode pair), proper resistors (R3 in Figure 4-1a) will be chosen in 
the electroporation circuit so that its resistance is comparable to what the cell sample load 
has for best electroporation performance. A microfluidic channel (500-µm wide, 300-µm 
deep, and 5-cm long) was milled on a piece of poly (methyl methacrylate) or PMMA 
board by a computer numeric control (CNC) machine. A piece of platinum wire (0.25 
mm in diameter) was pre-embedded in the PMMA board, perpendicular to the flow 
channel direction. It was then cut into two separate wire electrodes during the micro-
milling process with a gap size of 200 µm or longer (the actual separation distance 
between the Pt electrode pair is measured after device fabrication), as shown in Figure 4-
1b. Copper wire cables were then connected to the two Pt electrodes with the nanopulse 
electroporation circuit. To monitor gas bubble issues in nsEP, the nsEP microfluidic 
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device was mounted on the stage of an inverted microscope (Olympus IX71), and videos 
were taken to record the gas bubble evolution at different flow rates. 
 
Figure 4-1: Nanosecond pulse electroporation (nsEP) system. (a) The electric circuit 
design; (b) the microfluidic configuration with Pt electrodes integrated on the channel 
wall from both sides; (c, d) the pulse profile of individual nanosecond electric pulses at 
different pulse widths (c) and pulse voltages (d). 
4.2.4 Electroporation Setup and Process 
Cells were first centrifuged and re-suspended in fresh OPTI-MEM I (a serum-free 
medium) at a density of 1×107 cells/mL. Plasmid DNA (pMaxGFP) of 10 µg was then 
added in each electroporation sample (100 µL). These samples were first loaded into the 
microfluidic channel at a flow rate of 7 ml/hr to receive nsEP treatment. Nanosecond 
pulses with an electrical field of ~25 to 70 kV/cm, a pulse width of 400 to 800 ns, and a 
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pulse frequency of 1 to 400 kHz were applied across the two Pt wire electrodes. The cell 
solution experienced the nsEP treatment was continuously collected in a traditional 
electroporation cuvette downstream (with the parallel electrodes separated by 1 to 4 mm) 
to receive immediate standard electroporation (550 V/cm, one 10-ms pulse with a 
rectangular pulse profile). After the msEP treatment, cells were transferred to 12-well 
plates and cultured for 24 hours at 37 ℃ with 5% CO2 and 100% relative humidity before 
further analysis. 
4.2.5 Determination of DNA Delivery Efficiency 
The expression of pMaxGFP plasmids is evaluated both qualitatively by 
visualizing cells with green fluorescence within some representative areas under an 
inverted fluorescence microscope (Olympus, Japan) and quantitatively using flow 
cytometry (CytoFLEX PN B49006AE) with a laser wavelength of 495 to 519 nm. The 
results were analyzed with Cytexpert software, and 10,000 events were counted for each 
sample. The transfection efficiency of pMaxGFP is defined as the number of cells 
emitting fluorescence signal to the total number of counted cells in a sample (gated 
fluorescence signal of GFP). The GFP expression level is quantified as the mean 
fluorescence intensity of the whole counted cell population, which is correlated to the 
average dosage of plasmids delivered in individual cells. Their combination reflects a 
comprehensive picture of plasmid delivery and expression level in treated cells. In GFP 
plasmid expression kinetics experiments, transfected cells were distributed in 24-well 
culture plates and collected for flow cytometry measurements at various defined 
moments (1 hr, 1.5 hrs, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, and 24 hours) post-
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transfection. In PI dye uptake experiments, 1 µl PI dye solution (1µg/µl) was added to the 
cell solution (100 µl) and incubated for 20 min before further analysis or treatments. 
4.2.6 Measurement of Cell Viability 
MTS assays were used to evaluate cell viability. Briefly, 100 µL cells 24 hr post 
electroporation from each sample were harvested from their culturing cells and 
transferred to a 96-well plate. CellTiter 96 AQueous One solution (Promega, Madison, 
WI) of 20 µL was added to each well, and all samples were incubated at 37 ℃ for 1 hr. 
The absorbance signal of color formazan product from the reduction of MTS tetrazolium 
compound by dehydrogenase enzymes in metabolically active cells is measured at 492 
nm on an automated plate reader (Elx 800, Biotek, VT) to reflect the number of viable 
cells present in each sample under defined conditions. The cell viability is calculated as 
the absorbance signal ratio of an electroporated cell sample to what from the negative 
control cell sample, after extracting the absorbance background from the media. 
4.3 Result and Analysis 
4.3.1 Enhancement on Reporter Gene Transfection 
We hypothesize that nsEP treatment is capable of disrupting the nuclear 
membrane. Therefore, a combination of nsEP and msEP treatment was carried out and 
compared to an alternative treatment in which a chemical treatment using TCHD and 
msEP was combined. TCHD is amphipathic alcohol that is believed to reversibly collapse 
the permeability barrier of the nuclear pore complexes. It has been proven to facilitate the 
nuclear entry for plasmid DNA, though very toxic to the treated cells. Our comparison 
was made among three different cases: standard electroporation alone (designated as 
“msEP”), TCHD treatment followed by standard electroporation (designated as 
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“TCHD+msEP”), and nanosecond pulse treatment followed by standard electroporation 
(designated as “nsEP+msEP”). The pulse conditions of msEP were briefly optimized and 
set as one pulse of 550 V/cm for pulse strength and 10 ms for pulse duration on both 
CT26 and K562 cells. The pulse conditions of nsEP were optimized on three parameters 
separately: pulse voltage, pulse duration, and pulse frequency. As shown in Figure 4-2, 
the best nsEP conditions with a balance of high transfection efficiency and reasonable 
cell viability are also similar for these two cell lines. For most nsEP tested—unless 
specified—the following nsEP conditions are adopted in the following tests: 50 kV/cm 
(pulse strength), 600 ns (pulse duration), and 100 kHz (pulse frequency). Under these 
pulse conditions, the “nsEP+msEP” treatment receives higher transfection efficiency and 
lower toxicity in adherent cells CT26 (a model mouse fibroblast cell line for testing 
immunotherapy protocols and in studies on the host immune response) when compared to 
the other two treatments: the standard msEP alone and a combination of msEP with 
nuclear entry promotion agent, as shown in Figure 4-3. More cells express green 
fluorescence protein (GFP) for “nsEP+msEP” samples than the other two cases (Figure 
4-3a). Their difference in transgene expression was further quantified by flow cytometry 
measurement, with the mean GFP expression level in “nsEP+msEP” samples about three 
folds and two folds higher than that in “msEP alone” and “TCHD+msEP” samples, 
respectively (Figure 4-3b). This indicates that more plasmids were successfully 
transfected to CT 26 cells by the “nsEP+msEP” combination treatment. The transfection 
efficiency or number percentage of GFP positive cells was also measured and shown in 
Figure 4-3b as follows: “nsEP+msEP” (53.5% ± 1.0%), “TCHD+msEP” (33.3±0.8%) 
and “msEP alone” (24.3±0.1%). The combined “nsEP and msEP” treatment also 
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demonstrates a two-fold increase in the percentage of GFP positive cells than that from 
the standard electroporation treatment and 50% more than that which uses TCHD nuclear 
entry promotion reagent. Unlike the “TCHD+msEP” treatment in which the cell viability 
drops nearly 30% when compared to what in the “msEP alone” benchmark case, the 
“nsEP+msEP” treatment does not show apparent toxicity to CT26 cells, as shown in 
Figure 4-3c. The enhanced transgene expression in the “nsEP+msEP” combined 
treatment is not accompanied by the sacrifice of cell viability. To demonstrate its broad 
effectiveness, we also did the same treatments on a suspension cell line, K562 cells (a 
chronic myeloid leukemia cell line). As shown in Figure 4-4, similar transfection 
enhancement is also found on K562 cells. The standard “msEP alone” treatment receives 
a cell transfection of 27.6% ± 2.6%. In contrast, the introduction of TCHD treatment 
prior to msEP cell cytoplasm delivery gains a transgene expression of 45.4±2.0%, or a 
~18% increase (Figure 4-4b). The “nsEP+msEP” combination treatment further 
promotes the GFP expression level another ~18% more than what is achieved in the 
combined “TCHD+msEP” treatment, reaching 63.1% ± 2.8% (Figure 4-4b). The mean 
GFP expression level is also elevated to 1.8 times (“TCHD+msEP”) and 3.4 times 
(“nsEP+msEP”) when compared with the benchmark “msEP alone” treatment. These 
results prove that the combination of “nsEP+msEP” treatment more effectively enhances 
transgene expression of GFP for both adherent and suspension cells than the standard 
“msEP alone” or its combination with a nuclear entry promotion reagent. Different from 
what happened in CT-26 cells, no significant loss of cell viability occurs for the 
introduction of TCHD in K562 cells (Figure 4-4c). This may be attributed to their cancer 
cell nature and robustness to TCHD treatment. Nevertheless, significant enhancement of 
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plasmid transfection is achieved for the “nsEP+msEP” treatment without compromising 
cell viability loss. It is more effective over not only the standard electroporation (i.e., 
“msEP”) but also many well-adopted chemical transfection approaches (Figure 4-5), 
considering a balance of transgene expression and cell viability as well as the probe-to-
cell ratio. 
 
Figure 4-2: The pulse condition optimization for nsEP treatment on CT 26 cells(a-c) 
and K562 cells (d-f) based on a balance of transfection and cell viability. The 
transfection and cell viability for nsEP with pulses of different electric voltages (0.5-
1.4kV) under a fixed pulse frequency (100 kHz) and duration (600 ns) (a, c), different 
pulse duration (400-800 ns) under a fixed pulse voltage (1.0 kV) and frequency (100 
kHz) (b, e), and different frequencies (1 to 400 kHz) under a fixed pulse duration (600 




Figure 4-3: The transfection and cell viability of CT26 cells 24 hrs after transfection in 
three different cell transfection methods with a cell concentration of 107 cells/mL. (a) 
The phase-contrast (left) and fluorescent (right) images of cells treated by each 
method; (b) quantitative transgene expression presented both by transfection efficiency 
as the number percentage of GFP positive cells (data on the left group) and mean 
fluorescence intensity for average GFP dosage in individual cells (data on the right 
group, readings were divided by a factor of 105); (c) cell viability by MTS assays for 
cells treated by each method. In panels b and c, “msEP alone”: columns with green, 
upward diagonal stripes; “msEP+TCHD”: columns with orange, horizontal stripes; 
“nsEP+msEP”: columns with blue downward diagonal stripes. Significance t-test was 
performed with comparison to “msEP alone” treatment (n=3) with **P < 0.01 and *** 




Figure 4-4: The transfection and cell viability of K562 cells 24 hrs after transfection in 
three different cell transfection methods with a cell concentration of 107 cells/mL. (a) 
The phase-contrast (left) and fluorescent (right) images of cells treated by each 
method; (b) quantitative transgene expression presented both as transfection efficiency 
for the number percentage of GFP positive cells (data on the left group) and mean 
fluorescence intensity for average GFP dosage in individual cells (data on the right 
group, readings were divided by a factor of 105); (c) cell viability by MTS assays for 
cells treated by each method. In panels b and c, “msEP alone”: columns with green, 
upward diagonal stripes; “msEP+TCHD”: columns with orange, horizontal stripes; 
“nsEP+msEP”: columns with blue downward diagonal stripes. Significance t-test was 
performed with comparison to “msEP alone” treatment (n=3) with **P < 0.01 and *** 





Figure 4-5: Comparison of transfection performance of “nsEP+msEP.” electroporation 
treatment with other standard transfection methods in K562 cells. Standard 
electroporation is the same as the case designated as “msEP alone” in this paper; 
“polyplex (N/P=6.7)” represents polyplex transfection cases with samples prepared by 
vortex mixing polyethyleneimine (PEI, branched with MW=25K from Sigma-Aldrich) 
and pmaxGFP plasmid at an N/P ratio of 6.7 (the molar ratio of positively charged 
amine groups on PEI with negatively charged phosphate groups on DNA); “lipo2000 
(protocol)” represents lipofectamine 2000 (from Life Technologies) transfection cases 
following the vendor’s protocol (1 µg plasmid, 2 µL lipofectamine 2000 for 4 × 104 
cells); “lipo2000 (scale-up)” represents lipofectamine 2000 transfection cases having 
probe dosage scaled up according to theµ cell numbers that are used in our 
electroporation treatment (25 µg plasmid, 50 µL lipofectamine 2000 for 1 × 106 cells). 
The transfection is shown as mean fluorescence intensity measurement by flow 
cytometry (columns on the right-side group), and the cell viability is quantified via 
MTS assay (columns on the left side group), with three independent experiments.  
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4.3.2 Enhancement on Transgene Expression Kinetics 
As we hypothesized, nsEP treatment has advantages on cell nuclear membrane 
disruption, the transgene expression time should be significantly shortened for plasmid 
DNA probes with the permeable nuclear membrane and quick nuclear transport. To 
verify this hypothesis, we measured both the uptake of propidium iodide (PI) dye and 
expression kinetics the GFP plasmids using flow cytometry. As shown in Figure 4-6a, 
the uptake of PI dyes reaches 97.2% after the “nsEP+msEP” combination treatment. In 
contrast, the “msEP alone” treatment gets only 13.6%, which is only slightly higher than 
the case for merely incubating PI dyes with the cell solution (10.3%). Considering the 
membrane-impermeant nature of PI dyes and the fact that fluorescence signal emits only 
if PI dye molecules intercalate into the major groves of double-stranded DNA molecules, 
these results indicate that msEP alone cannot effectively disrupt the integrity of cell 
nuclear membrane, though the permeable cell membrane after msEP allows PI dyes to 
arrive in the cell cytosol. With additional nsEP treatment (i.e., for “nsEP+msEP” case), 
the dramatic increase of the fluorescence signal confirms that both the plasma membrane 
and the nuclear membrane of cells are successfully broken down to allow PI dyes to flush 
in and migrate all the way to the cell nucleus to conjugate with DNA molecules for 
fluorescence emission. To further prove the effectiveness of nsEP treatment on nuclear 
delivery, the expression kinetics of GFP plasmids in K562 cells is also monitored by 
measuring the DNA expression level at various moments of the first 24 hours after the 
“nsEP+msEP” combination treatment. The enhancement of the green fluorescent signal 
from GFP proteins was detected as early as 1.5 hours post-treatment, as shown in Figure 
4-6b. By 6 hours, the GFP expression level in the “nsEP+msEP” samples is almost the 
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same as what in the “msEP alone” treatment 24 hours post-transfection. From these 
results, we conclude that the contribution of nsEP towards the enhancement of 
transfection rate is likely the result of fast and massive transport of DNA plasmid across 
the cell nuclear membrane, so that early and efficient transcription process is initiated. 
 
 
Figure 4-6: (a) The PI dye uptake and (b) transgene expression kinetics of GFP 
plasmid in K562 cells for nsEP+msEP combination and msEP alone treatments. The 
nsEP conditions: 50 kV/cm (pulse strength), 100 kHz (pulse frequency), and 600 ns 
(pulse duration) and the msEP condition: 550 V/cm (pulse strength), one pulse, and 10 
ms (pulse duration). In panel b, “msEP alone”: columns with green, upward diagonal 
stripes; nsEP+msEP: columns with blue downward diagonal stripes. 
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4.3.3 Importance on The Treatment Order of nsEP and msEP 
Although nsEP helps make the nuclear membrane more permeable, significant 
enhancement of gene expression would not be achieved if the efficient crossing of the 
cell plasma membrane does not occur. We learned this from our early failed experimental 
efforts. In some of those early-stage experiments, the nsEP treatment was done alone 
under the same pulse conditions, but no successful plasmid transfection was found. This 
suggests that nanosecond pulses alone cannot make cell membrane permeable enough to 
allow effective cell uptake of plasmid DNA. In another set of experiments in which the 
msEP treatment was delayed one hour after the completion of nsEP treatment, we found 
the transgene expression enhancement effect also disappeared. These results suggest that 
without the quick introduction of plasmid DNA in the cell cytosol, the disrupted nuclear 
membrane might recover its integration before DNA molecules arrive there so that the 
nsEP treatment, which has the benefit of nuclear permeability enhancement, would be 
done in vain. In a different case, we switched the execution order of the nsEP and msEP 
treatment combination. When msEP is done before nsEP in the combined treatment 
(designated as “msEP+nsEP”), the transgene expression of GFP is not as high as its 
opposite combination order (“nsEP+msEP). As shown in Figures 4-7a & b, the GFP 
expression for the “msEP+nsEP” treatment receives a transfection efficiency of 
51.4±3.6%, about 12% lower than what with the combination order as “nsEP+msEP” 
(63.1% ± 2.8%) at the same pulse conditions. Moreover, the cell viability of the 
“msEP+nsEP” treatment also drops about 10% when compared to what in the 
“nsEP+msEP” cases (Figure 4-7c). This suggests that having already disrupted cell 
membranes makes further polarization of cell nuclear membranes less effective. The 
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followed high-frequency nanosecond pulses cause more loss of ions or molecules from 
the treated cells than what happened in the “msEP alone” treatment. Their damage to 
cells is so severe that the promotion to the nuclear delivery of DNA is mostly offset by 
the slow recovery of the cellular membrane and some metabolic functions of the treated 
cells, resulting in their low survival rate. This is probably one primary reason that 
undesired low transfection efficiency and/or cell viability were received in other 




Figure 4-7: The effect of the combination order of msEP and nsEP on DNA delivery: 
(a, b) transfection efficiency and (c) cell viability. In panels b & c, “msEP alone”: 
columns with green, upward diagonal stripes; “msEP+nsEP”: columns with cyan, 
vertical stripes; “nsEP+msEP”: columns with blue downward diagonal stripes. 
Significance t-test was performed with n=3 and ** represents P < 0.01 and *** for P< 
0.005 with comparison made to “msEP alone” treatments. 
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4.3.4 Contribution of Microfluidics on Electroporation Enhancement 
The introduction of microfluidics during nsEP enables close patterning of Pt 
electrodes so that a low pulse voltage is sufficient to meet the required field strength for 
effective nanosecond treatment, besides its additional benefit of high throughput on cell 
processing. More importantly, we found a microfluidics configuration helps suppress the 
gas bubble evolution and Joule heating issues that often lead to low cell viability during 
nanosecond pulse treatment. As shown in Figures 4-8a & b, no visible gas bubbles are 
found near the electrodes with a 100  magnification at the regular flow rate in our nsEP 
treatment (7 ml/hr). However, if the cell flow is slowed down, gas bubbles are clearly 
observed to appear continuously near the electrode surface when the nanosecond pulse 
signal is turned on (Figures 4-8c - 4-8f). The generated gas bubbles grow quickly on the 
electrode surface while they are eventually taken away by flow downstream when getting 
too big. The slower the liquid flow, the bigger the gas bubbles are. This suggests that the 
suppression of electrohydrolysis and Joule heating phenomena by this microfluidic nsEP 
system comes from the quick takeaway of bubbles from their generation spots (the Pt 
electrodes) so that the associated gas bubble evolution issues are minimized. As a result, 
high cell viability and better enhancement of transgene expression (i.e., more transfected 
cells survived the electroporation treatment with normal metabolism) are achieved 




Figure 4-8: Gas bubble formation and evolution dynamics in microfluidic nsEP 
treatment at various flow rates. Photos of microfluidic device without nsEP treatment 
(a) and with nsEP treatment of a K562 cell solution flowing at 7 ml/hr (b), 6 ml/hr (c), 
5 ml/hr (d), 3 ml/hr (e), and 0 ml/hr (f). The scale bars represent 100 µm. (Note: texture 
shown in the channel region of each image comes from winkles of scotch tape sealing 




The generation of electric pulses with both high-voltage field strength and a 
mixture duration of a millisecond and nanosecond duration is not trivial. Severe signal 
entanglement and profile distortion often occur. Two design features are applied in our 
system to avoid these issues. First, we separate the nanosecond pulse generator and high-
voltage supply units into two different electric circuits, which are bridged by a MOSFET 
switch. The frequency (Hz) and duration (ns) of the nanosecond pulses are decided by the 
pulse signal generator while the high voltage electric field imposed on cells is supplied by 
the pre-charged capacitor through the high voltage supply circuit. The decoupling of the 
pulse voltage and duration (and frequency) in our nsEP treatment helps maintain an 
appropriate pulse profile when some other pulse parameters are changed. Together with 
the Pt wire electrode pair, nanosecond pulses in our nsEP system have ultra-short 
responding time, well-defined signal profile, and stable pulse voltage. For example, when 
the pulse width or amplitude is changed, the waveform (amplitude or width) of those 
nanosecond pulses, including the primary rectangular part and the reflection tail, is well 
retained. Another design we adopted to avoid signal entanglement lies in the separation 
of the nsEP and msEP treatments with different devices. A microfluidics-based nsEP 
treatment is followed by a cuvette-based standard msEP electroporation. Such 
configuration separation allows the complete decoupling of the two types of pulse signals 
in nsEP and msEP treatments. The pulse conditions for each treatment can be tuned 
separately without interactions from the other, making the comparison and optimization 
of electroporation protocols easier and more reliable. 
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Besides quick responding time, the proximity placement of the two Pt wire electrodes on 
the sidewall of the microfluidic channel further allows relatively low applied voltage or 
energy dose and long pulse duration in our nsEP treatment. This helps to collapse the 
nuclear membrane more effectively without much cell toxicity, unlike what is observed 
in irreversible electroporation with ultrashort pulses. Moreover, the introduction of a 
microfluidic configuration in the nsEP treatment mitigates electrohydrolysis-induced side 
effects such as gas bubble evolution and Joule heating, another significant negative 
impact of other nanosecond pulse treatment on permanent damage to cells and/or 
consequent cell apoptosis. Gas bubble formation is normal in electroporation, contributed 
by water electrohydrolysis. With the presence of gas bubbles, they disturb the 
instantaneous local electric field, making the followed pulse disruption on neighbor cells 
much less effective. Moreover, the accompanied Joule heating further elicits the bubble’s 
growing, rising, and bursting (Kim et al., 2007). Since many cells are trapped around gas 
bubbles, such bubble evolution dynamics causes further detrimental damage to cells, 
varying from the impact on cell physiological response to complete cell lysis. In our 
microfluidic nsEP treatment step, gas bubbles were generated on the electrode surface, 
like in most studies employing electroporation. However, the generated gas bubbles were 
quickly taken downstream by flow, away from the Joule heating source (i.e., near Pt 
electrodes) before growing too big. Such suppression of gas bubble evolution is one key 
to the success of this microfluidic “nsEP+msEP” combination treatment. Similar gas 
bubble evolution dynamics were also found in our early studies on cuvette based standard 
msEP treatment (Wang et al., 2009). With still fluid in a cuvette that stands straight up, 
gas bubbles are generated, further grow, rise, aggregate, and burst when arriving at the 
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air-liquid interface. Strong convection of liquid caused by gas bubble dynamics during 
pulsation period not only traps and damages cells (particularly when burst) but also 
dramatically affects the local electric field of the followed pulses. Although the gas 
bubble issues vary with the pulse conditions such as pulse type, strength, and duration, it 
is probably another cause of the disappointing transgene expression outcomes in some 
early nanosecond pulse studies employing cuvettes in their entire treatments (Chopinet et 
al., 2013). As this issue is primarily suppressed in this microfluidic “nsEP+msEP” 
treatment, it is not surprising that better enhancement of transgene expression and high 
cell viability are achieved simultaneously. 
4.5 Conclusions 
In summary, we developed a new microfluidic electroporation approach with a 
combination of nanosecond and millisecond pulses to enhance plasmid DNA transfection 
without sacrifice on cell viability. For adherent cells CT26 and suspension cells K562, 
transgene expression of GFP plasmid is more than doubled at the same cell viability 
levels as in standard msEP electroporation. Promotion on nuclear entry by nanosecond 
pulses and the suppression of gas bubbles with the microfluidic operation is believed to 
be the two major contributions by this new system on the transfection enhancement. 
Having nsEP first and msEP followed immediately is found to work more effectively 
than other cases with either the opposite operation order or having a long waiting period 
between the two types of pulse treatments. This new microfluidic nsEP and msEP 
combination treatment not only facilitates plasmid delivery and expression but also 
eliminates the electrohydrolysis-induced apoptosis and low cell viability issues 
commonly tied with nanosecond pulse treatments. Its success may benefit many biology 
71 
 
studies and clinical practice in understanding gene functions, controlling cellular signals, 





























COUPLING NANOSECONDS ELECTROPORATION AND CARBON 
NANOTUBE MICROPILLAR ELECTROPORATION ENHANCED 
GENE PROBES DELIVERY IN WHOLE BLOOD THERAPY 
 
5.1 Introduction 
As a new and proven method, immunotherapy has gradually been recognized by 
the cancer treatment community (Khalil et al., 2016). It activates or stimulates the 
patient’s immune system to allow better recognize tumor antigens or specific aggregation 
and/or attack tumor cells (Davis, 2000; Oiseth & Aziz, 2017). However, in current 
immunotherapy treatments, only some specific types of cells, such as T cell or DC, can 
be treated. Besides their low transfection efficiency, the treated cells have a low survival 
rate and further, in vitro expansion, the cell population is often needed. Therefore, a 
general immunotherapy method includes performing lymphatic injection on the patient or 
isolate the patient’s blood to extract specific lymphocytes first. The collect cell samples 
are then received in vitro transduction using viral vectors. After further cell expansion, 
the mature cells are eventually injected back to the patient to conduct immunotherapy. 
With two unavoidable surgery involvements, this approach always causes significant and 
long-term pain for patients.  
To solve this problem, we coupled our nanoseconds electroporation and carbon 





implemented electroporation technologies demonstrated in chapters 3 and 4, to treat 
primary T lymphocytes and whole blood samples in this chapter. Due to its quick 
completion of electroporation treatment (within seconds), the cell transfection step can be 
done in the first sampling step and the second surgery is therefore avoided. Specifically, 
we first use nanosecond pulse electroporation to pre-treat the primary blood cells to 
weaken the integration of their cell membrane and more important to create pores on the 
nuclear membrane. Then millisecond pulses via Carbon Nanotube Micropillars 
Electroporation are applied to homogeneously treat cells of various types and sizes. 
Primary red blood cells and T cells were transfected separately with the same pulse 
conditions using GFP encoding plasmids or mRNA with therapeutic genes to complete 
the optimization. Because of the limited primary T cell supply and the huge cell 
population difference of erythrocytes, reticulocytes, and leukocytes in whole blood 
samples, we simplified our treatment by using a mixture of normal blood cell samples 
(most are red blood cells) and K562 cells to simulate different situations and test potential 
interference of transfection performance for samples with different populations of red 
cells and immune cells. Because of the no-nucleus fact of mature red blood cells, 
microRNA miR-29b was used as the presenting probe to evaluate the electroporation 
transfection efficiency in red blood cells. After transfection, the therapeutic functions of 
miR-29b in our model blood cells post-transfection can be conveniently monitored by 
measuring some targeting protein levels in K562 cells this microRNA (miRNA) probe 
commonly regulates.  
Among different oligonucleotides, miRNA is a small non-coding single-stranded 
small-molecule RNA with a length of about 20 to 25 nucleotides (a few are less than 20 
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nucleotides). Many studies have shown that miRNA can inhibit target mRNA translation 
or induce shear through specific base pairs (Lee et al., 1993). Thereby down-regulating 
gene expression at the post-transcriptional level, promoting rapid deadenylating of target 
mRNA, and making it easy to degrade are among the primary mechanisms for miRNA 
inhibition on gene expression (Wu et al., 2006). Among different therapeutic miRNA, 
miR-29b can regulate tumor cell proliferation, differentiation, apoptosis, invasion, 
metastasis, and drug resistance in several pathways (Jiang et al., 2014; Alizadeh et al., 
2019). It can directly target on DNMT3B gene to inhibit the process of DNA 
methylation, thereby alleviating tumorigenesis. It can also bind to the CDK6 gene, so that 
the cell cycle is trapped in the G1 phase, thereby inhibiting the proliferation of tumor 
cells. It can also target on MCL-1 gene and inhibit its expression, thereby promoting 
cancer cells to apoptosis. Therefore, we evaluated the expression level of CDK6, 
DNMT3b, and MCL-1in K562 cells to confirm the downregulation function of miR-29b 
probes that being loaded in blood samples. 
In this chapter, GFP mRNA transfection efficiency was first tested on primary T 
cells obtained from the spleen. The transfection efficiency enhancement of nsEP+CNTPs 
in red blood cells was then evaluated using microRNA. After that, a mixture of primary 
red blood cells and K562 lymphoblast in different ratios were evaluated for both DNA 
plasmids and microRNA transfection efficiency. And at last,  the reservation of the 
therapeutic functions of the delivered probes was evaluated by measuring the expression 
efficiency of miR-29b target genes (CDK6, DNMT3b, and MCL-1) in leukemia cells. 
75 
 
5.2 Materials and Methods 
5.2.1 Materials and Reagents 
GFP mRNA was synthesized from pGEM4Z/GFP/A64 DNA plasmids template 
with a T7 mScript Standard mRNA Production System, purchased from CellScript, 
Madison, WI, USA. DNA plasmids probe with pMaxGFP reporter genes were purchased 
from Lonza, Inc. The miRIDIAN microRNA human has-miR-29b-3p mimic with miR 
sequence: 5-UAGCACCAUUUGAAAUCAGUGUU-3 was purchased from Thermo 
Scientific (Pittsburgh, PA). All other cell culture reagents were purchased from Life 
Technologies (Carlsbad, CA), and all the chemicals were purchased from Sigma-Aldrich 
unless specified. 
5.2.2 Cell Culture 
Primary CD8+ T cells were isolated from the spleens under aseptic conditions. 
Individual spleens were homogenized to release splenocytes, in 5 ml RPMI 1640 
medium. A human chronic myelogenous leukemia (CML) cell line, K562 Cells (ATCC, 
CCL-243) and beef cattle whole blood (obtained from Louisiana Tech University, School 
of Agricultural Sciences & Forestry) were used in the electroporation test. These cells 
were cultured in RPMI 1640 medium (supplemented with 10% FBS, 1% L-Glutamine, 
and Penicillin/streptomycin). All cultures were maintained at 37 ℃ with 5% CO2 and 
100% relative humidity. 
5.2.3 Electroporation Setup and Process 
Cells were first centrifuged and re-suspended in fresh OPTI-MEM I (a serum-free 
medium) at a density of 1 × 106 cells/mL. Plasmid DNA (pMaxGFP) of 10 µg or 
microRNA probes (has-miR-29b) of 100 pmol were then added in each electroporation 
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sample (100 µL). These samples were first loaded into the microfluidic channel at a flow 
rate of 7 ml/hr to receive nsEP treatment. Nanosecond pulses with an electrical field of 
~15 kV/cm, a pulse width of 600 ns, and a pulse frequency of 100 kHz were applied 
across the two Pt wire electrodes. The cell solution experienced the nsEP treatment was 
continuously collected and loaded onto the CNTPs surface (CNTPs was considered as a 
positive electrode). A piece of ITO-coated Glass (ITO Coated Glass was considered as a 
negative electrode) with a PDMS gasket (~200 µm thickness) was covered onto the cell 
solution sample. Electric pulse was added onto these samples (2.5 kV/cm, single 10-ms 
pulse with a rectangular pulse profile). After the electric pulse, the ITO-coated Glass was 
removed from CNTPs. Cells were collected and transferred to 12-well plates and cultured 
for 24 hours at 37 ℃ with 5% CO2 and 100% relative humidity prior to further analysis. 
5.2.4 Determination of DNA Delivery Efficiency 
The expression of pMaxGFP plasmids is evaluated both qualitatively by 
visualizing cells with green fluorescence within some representative areas under an 
inverted fluorescence microscope (Olympus, Japan) and quantitatively using flow 
cytometry (CytoFLEX PN B49006AE) with a laser wavelength of 495 to 519 nm. The 
results were analyzed with Cytexpert software, and 10,000 events were counted for each 
sample. The transfection efficiency of pMaxGFP is defined as the number of cells 
emitting fluorescence signal to the total number of counted cells in a sample (gated 
fluorescence signal of GFP). The GFP expression level is quantified as the mean 
fluorescence intensity of the whole counted cell population, which is correlated to the 
average dosage of plasmids delivered in individual cells. Their combination reflects a 
comprehensive picture of plasmid delivery and expression level in treated cells. 
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5.2.5 Determination of microRNA Delivery Efficiency 
The miR-29b delivery efficiency was evaluated by the expression level of miR-
29b. To measure expression levels, the total RNA was first reverse transcription into 
cDNA, and a Realtime-PCR was conducted. The expression level was determined by the 
ΔΔCt method and normalized to endogenous controls. 
5.2.6 Total RNA Extraction 
Total RNA was extracted using TRIzol reagent (Life Technologies, Carlsbad, 
CA). Cells were harvested by centrifugation, and the culture medium was removed. And 
250 µl TRIzol reagent was added to each sample (containing approximately 8 to 10 x 105 
cells). Samples were lysed by pipetting several times and incubated for 5 min at room 
temperature. The nucleoprotein complex was dissociated completely. 125 µl chloroform 
was added to each sample, and the tubes were shaken vigorously for 15 s followed by 3 
min incubation at room temperature. Then all the samples were centrifuged with 12,000 
rpm for 15 min at 4 ℃ and all the samples were separated into a colorless upper aqueous 
phase, interphase, and a lower red chloroform phase. The upper aqueous phase was 
transferred into new tubes by gentle pipetting without drawing any of the interphases, and 
500 µl 100% isopropanol was added into each of aqueous phase tubes, followed by 10 
min incubation at room temperature. The samples were centrifuged at 12,000 rpm for 10 
min at 4 ℃. And the supernatant was removed. To wash the RNA pellet, 200 µl 75% 
ethanol was added into each tube. Samples were vortexed briefly and centrifuged at 7500 
rpm for 5 min at 4 ℃. The supernatant was removed. The RNA pellets were air-dried for 
5 to 10 min. 20µl RNase-free water was added into each tube, and all the samples were 
incubated at 60 ℃ for 10 min. Then the RNA was ready for downstream application. 
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5.2.7 Reverse Transcription PCR 
The Taqman® microRNA Reverse Transcription Kit (Life Technologies, 
Carlsbad, CA) was used for microRNAs reverse transcription. The reagents were first 
allowed to thaw on ice. The total volume of 15 µl reaction was prepared in a 
polypropylene tube, including 0.15 µl dNTP mix (100 mM total), 1 µl MultiscribeTM RT 
enzyme (50 U/µl), 1.5 µl 10X RT PCR buffer, 0.19 µl RNase inhibitor (20 U/µl), 4.16 µl 
nuclease-free water, 3 µl primer and 5 µl RNA sample (~1000 ng). the thermal cycler 
was programmed as follows: 30 min at 16 ℃, 30 min at 42 ℃, 5 min at 85 ℃ and hold at 
4°C. 
5.2.8 qRT-PCR Amplification 
The resulting cDNA from reverse transcription reaction was amplified by qRT-
PCR with TaqMan™ Gene Expression Master Mix (Thermo Scientific, Pittsburgh, PA). 
The total volume of 20 µl reaction was prepared in a polypropylene tube, including 10 µl 
TaqMan™ Gene Expression Master Mix, 1 µl 20 X TaqMan® assay and 9 µl cDNA 
template. The thermal cycler was programmed as follows: 10 min at 95 ℃ for 
polymerase activation, then 40 PCR cycles with 15 seconds at 95 ℃ for denaturing and 1 
min at 60 ℃ for annealing. The relative gene expression was determined by the ΔΔCt 
method. The mature miR-29b expression was normalized to endogenous control RNU48 
and relative to the untreated control cells. The expression of CDK6, DNMT3B, and 
MCL-1 mRNAs was normalized to endogenous controlled GAPDH and relative to the 
untreated controlled cells. 
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5.3 Results and Discussion 
5.3.1 Enhanced mRNA Transfection in Primary T Cells 
To demonstrate the enhancement of Nanosecond Pulses electroporation coupling 
Carbon Nanotube Micropillars Electroporation (nsEP+CNTPs) on transfection efficiency 
for the whole blood immunotherapy, we need to demonstrate the genetic probes 
transfection efficiency enhancement on leukocytes first as they are the primary target in 
immunotherapy. However, since the proportion of leukocytes in whole blood cells is very 
limited (less than 5%), we chose to isolate the primary T cells from the whole blood for a 
separate test first. The transfection enhancement was demonstrated with the GFP mRNA 
probe (in vitro transcript from pGEM4Z/GFP/A64 GFP DNA plasmids). We 
electroporated 1 × 107 primary T cells with 5 µg of GFP mRNA with nsEP+CNTPs and 
commercial electroporation device (BTX). Transfection efficiency was measured by flow 
cytometer after 24 hrs. As shown in Figure 5-1 (a), the transfection efficiency with the 
nsEP+CNTPs system (6.1% for primary T cells) is generally better than that from BTX 
(1.2%). Although the overall efficiency is not very high, for primary T cells, the 
transfection efficiency brought by the new coupling electroporation system is already ~5 
folds multiple of the commercial electroporation device (BTX). These results confirm 
that the enhancement of the nsEP+CNTPs system on mRNA transfection for primary T 
cells. This result was compared to the transfection efficiency promotion of the 
nsEP+CNTPs electroporation system on K562 lymphoblast. In that experiment, 1 × 107 
K562 cells with 10 µg of GFP plasmids were electroporated by nsEP+CNTPs and 
commercial electroporation device (BTX). Transfection efficiency was measured by flow 
cytometer after 24 hrs. As shown in Figure 5-1 (b), the standard “BTX” treatment 
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receives a cell transfection of 24.2% ± 3.6%. In contrast, the nsEP+CNTPs treatment 
gains a transgene expression of 72.4±6.3%, or a ~ 3 folds increase. These results show 
similar effectiveness of this nsEP+CNTPs electroporation system on genetic probe 
transfection. Considering their similar cell size and electrical properties as well as similar 
transfection performance, we added K562 lymphoblast in blood cell samples as model 
blood cell mixture in later transfection experiments to enhance the result statistics of 
leukocyte transfection given the limited primary T cell resource.  
 
Figure 5-1: Result for nsEP + CNTPs & BTX enhanced GFP mRNA/GFP DNA 
Plasmids delivery in primary T cells (a) and K562 lymphoblast (b).  
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5.3.2 Enhanced microRNA Probes Transfection in Red Blood Cells and 
Lymphoblast 
To demonstrate the gene delivery enhancement function of our device in the 
whole blood, we used microRNA as our genetic test probe (miR-29b). This comes from 
the fact that more than 90% of whole blood cells are red blood cells. Without a nucleus, 
red blood cells cannot replicate and transcribe DNA probes, so DNA plasmids were not 
used in this experiment. Also, because microRNA and mRNA used in immunotherapy 
are similar in molecular components, we used microRNA as our genetic probes here. In 
this experiment, we used the same electroporation condition on both red blood cells and 
K562 cells as we did in primary T cells without further optimization to mimic closely the 
treatment conditions in future whole blood immunotherapy. Compared to the commercial 
electroporation system, the mature miR-29b expression increased ~2.5 folds in the K562 
lymphoblast cells and ~3 folds in the whole blood cells at 24 hours after electroporation. 
This increase demonstrates that the nsEP+CNTPs device had enhanced miR-29b 




Figure 5-2: Result for nsEP + CNTPs & BTX enhanced miR-29b delivery in Red 
blood Cells (a) and K562 cells (b). 
5.3.3 Enhanced DNA Plasmids Probes Transfection in Blood Cell Mixture 
To evaluate DNA plasmid delivery efficiency enhancement in blood cell samples 
at different ratios, we set three model samples in the following proportions: 50% whole 
blood cells and 50% K562 Cells; 80% whole Blood Cells and 20% K562 Cells; 90% 
whole Blood Cells and 10% K562 Cells, and the total cell number is 1 million per each 
sample. We electroporated these samples with 10 µg of pMaxGFP plasmids with 
nsEP+CNTPs and BTX. Transfection efficiency was measured by flow cytometer after 
24 hrs. Because red blood cells do not have a nucleus and cannot transcribe the plasmids, 
the expression of GFP mainly comes from K562 cells and the small portion of leukocytes 
in blood samples. The purpose of mixing red blood cells here is to test the leukocytes 
(K562 cells were added here to increase the represented percentage of leukocytes) uptake 
efficiency of DNA plasmids under the interference of many small red blood cells. This 
helps estimate the interference of the large presence of red blood cells to the electric field 
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and the leukocyte uptake of plasmids. As shown in Figure 5-3 and Figure 5-4, compared 
to BTX method, the pMaxGFP plasmids transfection efficiency is ~1.8 folds when the 
cell type ratio is 50% whole Blood Cells and 50% K562 Cells, ~1.6 folds when the cells 
type ratio is 80% whole Blood Cells and 20% K562 Cells, and ~2.4 folds when the cells 
type ratio is 90% whole Blood Cells and 10% K562 Cells in those the cells that were 
electroporated with nsEP+CNTPs at 24 hours after electroporation (Figure 5-5). The 
transfection efficiency of K562 electroporated alone is a little higher than the cell mixture 
samples. This result indicates that in the complex blood environment, under the 
interference of red blood cells, the nsEP+CNTPs electroporation transfection efficiency is 
still higher than the traditional electroporation method and the presence of a large 
population of red blood cells does not affect significantly the transfection performance. 





Figure 5-3: The Flow Cytometry Analysis Results of three Blood Model samples: 50% 
Whole Blood Cells and 50% K562 Cells; 80% Whole Blood Cells and 20% K562 Cells; 





Figure 5-4: The Flow Cytometry Analysis Results of three Blood Model samples: 50% 
Whole Blood Cells and 50% K562 Cells; 80% Whole Blood Cells and 20% K562 
Cells; 90% Whole Blood Cells and 10% K562 Cells. They were electroporated by 




5.3.4 Enhanced microRNA Probes Transfection in different Red Blood/ 
Lymphoblast Cells ratio 
To test the microRNA delivery efficiency of cells in different sizes and types, we 
mixed red blood cells and K562 cells at different ratios. In this section, we set three 
model samples in the following proportions: 50% whole Blood Cells and 50% K562 
Cells; 80% whole Blood Cells and 20% K562 Cells; 90% whole Blood Cells and 10% 
K562 Cells. This is to simulate the complex cellular environment. Electroporation was 
 
Figure 5-5: DNA plasmids transfection efficiency result for nsEP + CNTPs & BTX in 
different cells ratio models. 
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applied to these three samples with 100 pmol miR-29b by nsEP+CNTPs device and 
traditional electroporation device (BTX). Mature miR-29b transfection efficiency was 
determined in these three samples. As shown in Figure 5-6, compared to the benchmark 
of commercial electroporation treatment, the mature miR-29b expression was increased 
~1.6 folds when the cell type ratio is 50% whole Blood Cells and 50% K562 Cells, ~2.2 
folds when the cells type ratio is 80% whole Blood Cells and 20% K562 Cells, and ~2.3 
folds when the cells type ratio is 90% whole Blood Cells and 10% K562 Cells in those 
the cells that were electroporated with nsEP+CNTPs at 24 hours after electroporation. 
This increase demonstrated that the nsEP+CNTPs device had enhanced miR-29b 
expression when there are different cell types or sizes. This result indicates that when the 
cell size varies greatly, the commercial electroporation device cannot function well, while 





Figure 5-6: Mature miR-29b Expression in different Whole Blood Cells and K562 
Cells ratio models. 50% Whole Blood Cells and 50% K562 Cells; 80% Whole Blood 
Cells and 20% K562 Cells; 90% Whole Blood Cells and 10% K562 Cells. 
5.3.5 Enhaced microRNA Probes Down-Regulation Function Efficiency in 
Lymphoblast Cells 
To further demonstrate the function reservation of the delivered miR-29b 
microRNA, we also tested the down-regulation efficiency of miR-29b targeting genes. 
Similarly, because red blood cells have no nuclei, the downregulation of those target 
protein levels is only contributed by K562 cells. As shown in Figure 5-7, for cells that 
were electroporated by nsEP+CNTPs, the target genes DNMT3B, MCL-1 and CDK6 
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were downregulated by ~60%, ~50%, and ~60%, respectively, compared to the cells that 
were electroporated by the commercial electroporation system, in which the target genes 
DNMT3B, MCL-1, and CDK6 were down-regulated by ~40%, ~15%, and ~45%, 
respectively. The expression of targeted genes was more efficiently downregulated in 
cells electroporated by nsEP+CNTPs compared to by commercial electroporation system.  
 
Figure 5-7: Result for nsEP + CNTPs & BTX enhanced the downregulation of 
targeting genes in K562 cells.  
5.4 Conclusions 
This chapter focuses on the mRNA, DNA plasmids, and microRNA delivery with 
the nsEP+CNTPs electroporation method in primary T cells and whole blood samples. 
CNTPs were used to enhance the strength of the local electric field for different types and 
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sizes cells and conjugated with the Nanosecond pulses to enhance the genetic probe 
delivery efficiency. The genetic probes release, expression, and function on target genes 
were evaluated. Based on the higher expression efficiency of the nsEP+CNTPs, we 
concluded that this method performs better than the traditional electroporation method in 
whole blood cells. Since DNA/RNA based vaccines therapy is a very important treatment 
method in immunotherapy, the nsEP+CNTPs method provides a favorable prospect for 
non-viral gene delivery-based immunotherapy. We also expect that this new type of 





CONCLUSIONS AND FUTURE WORK 
 
6.1 Conclusions 
Electroporation is a practical non-viral cell transfection approach for its balance 
on the transfection efficiency and cell viability, no restrictions of the probe or cell type, 
and operation simplicity. In this dissertation, we investigated the improvement of 
electroporation performance through the introduction of carbon nanotube micropillars 
electroporation and nanosecond pulses electroporation. Results are concluded as follows:  
With the application of carbon nanotube micropillars electroporation, we 
demonstrated better DNA, siRNA and microRNA delivery efficiency in mammalian cell 
electroporation, and some loss on the cell viability, but not statistically significant. By 
apply carbon nanotube micropillars electroporation, we observed that all size cells could 
be uniformly electroporation, but not only the middle size cells. The delivery efficiency 
and cell viability were evaluated with both adherent cells (i.e., CT-26) and suspension 
cells (i.e., K562). Although more DNA and RNA probes were taken up by cells under the 
influence of CNTPs, no significant cytotoxicity was produced compared to the 
commercial electroporation system. In general, the CNTPs showed 2 to 3 folds 
improvement on the transfection efficiency of the plasmid DNA probes while the cell 
viability showed no significant difference compared with the commercial electroporation 
system. As for the enhancement of the RNA probes delivery, there was a 2.5 folds 
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improvement showed from the gene downregulation. According to the results of the flow 
cytometer, the improvement of transfection efficiency is mainly due to the larger size or 
smaller size cells got transfected, in which the commercial electroporation system cannot 
complete transfection efficiently. This success may serve as a safe and effective non-viral 
gene delivery to help multiple cell sizes and types of immunotherapy work effectively. 
We have also developed a new microfluidic electroporation approach with a 
combination of nanosecond and millisecond pulses to enhance plasmid DNA transfection 
without sacrifice on cell viability. For adherent cells (i.e., CT-26) and suspension cells 
(i.e., K562), transgene expression of GFP plasmid is more than doubled at the same cell 
viability levels as in standard msEP electroporation. Promotion on nuclear entry by 
nanosecond pulses and the suppression of gas bubbles with the microfluidic operation is 
believed to be the two major contributions by this new system on the transfection 
enhancement. Having nsEP first and msEP followed immediately is found to work more 
effectively than other cases with either the opposite operation order or having a long 
waiting period between the two types of pulse treatments. This new microfluidic nsEP 
and msEP combination treatment not only facilitates plasmid delivery and expression but 
also eliminates the electrohydrolysis-induced apoptosis and low cell viability issues 
commonly tied with nanosecond pulse treatments. Its success may benefit many biology 
studies and clinical practice in understanding gene functions, controlling cellular signals, 
screening drugs, and applying cell-based therapeutic technologies. 
We did some preliminary tests on model blood cell mixture, using primary red 
blood cells and T cells as well as the whole blood cells. Further studies on its 
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effectiveness on the whole blood, particularly in those different primary immune cells 
and red cells carry on therapeutic probes will be studied.  
6.2 Future Work 
In this dissertation, we have already demonstrated by several studies that coupling 
nanosecond electroporation and Carbon Nanotube Micropillars Electroporation can 
achieve a better electroporation efficiency than commercial electroporation device in 
various cells including T cells and blood cells. Unfortunately, limited by the cells and 
animal resources, we have not extensively applied this new coupling system on real 
patient T cells, blood cell samples, or the animal models yet. So, in the future, we hope to 
cooperate with research groups in MD Anderson and Southwestern medical centers to 
apply this mRNA/DNA probes vaccine to T cells and whole blood cell samples by the 
nsEP+CNTPs system. Two types of immunotherapy strategies will be evaluated with this 
nsEP+CNTPs system to transfect mRNA encoding probes (e.g., Ovalbumin) to T cells 
and the whole blood samples. 
For direct T-cell based immunotherapy, primary T cells will be collected, purified, 
and transfected with various DNA and mRNA probes. Both activated and non-activated 
T cells will be transfected. Optimal pulse conditions and loading dosages of therapeutic 
probes will be established, the loading efficiency of DNA and mRNA probes together 
with their expression kinetics will be monitored following 3 to 7 days post-delivery. After 
transfection, the treated T cells can be co-cultured with cancer cells (e.g., Melanoma) to 
evaluate the functions of those treated T cells. By testing the inhibitory effect of cancer 
cells and the cytokines expressed by cytotoxic T lymphocyte, we can determine if the 
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primary T cells with the mRNA probes are functional after receiving nsEP+CNTPs 
electroporation.  
The nsEP+CNTPs system can also be used to deliver mRNA vaccines to human 
whole blood samples for vaccine-type immunotherapy. In this treatment, all cells in the 
blood samples will receive a quick electroporation treatment by the nsEP+CNTPs 
system. Encoding cancer antigens mRNA/DNA vaccines will be delivered to different 
types of blood cells, including lymphocytes, reticulocytes, and erythrocytes. The 
mRNA/DNA loading level in each of these blood cell types can be measured to 
determine the electroporation efficiency of the nsEP+CNTPs system. The blood cells 
containing mRNA/DNA vaccines will then be co-cultured with Antigen Presenting Cells 
(APCs) and then T cells. Those trained T cells will then be co-cultured with target cancer 
cells like in T cell immunotherapy described early. The T Cell Receptor proteins on the T 
cells’ membrane, the secretion efficiency of cytokines, and the inhibitory efficiency of 
cancer cells can then be measured to test the effectiveness of the nsEP+CNTPs system in 
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